drug,ccle_drug_name,ccle_target,gdsc_drug_name,gdsc_synonyms,gdsc_target,gdsc_target_pathway,ctrp_drug_name,ctrp_target,ctrp_target_description,synonyms,targets
(5z)-7-oxozeaenol,,,(5Z)-7-Oxozeaenol,"5Z-7-Oxozeaenol, LL-Z1640-2",TAK1 ,"Other, kinases",,,,5Z-7-Oxozeaenol; LL-Z1640-2; (5Z)-7-Oxozeaenol,TAK1
16-beta-bromoandrosterone,,,,,,,16-beta-bromoandrosterone,,dehydroepiandrosterone (DHEA) analog,16-beta-bromoandrosterone,NaN
"1s,3r-rsl-3",,,,,,,"1S,3R-RSL-3",GPX4,synthetic lethal with HRAS in engineered cells; inhibitor of GPX4,"1S,3R-RSL-3",GPX4
3-cl-ahpc,,,,,,,3-Cl-AHPC,NR0B2,binder of nuclear receptor SHP,3-Cl-AHPC,NR0B2
5-fluorouracil,,,5-Fluorouracil,5-FU,Antimetabolite (DNA & RNA),Other,,,,5-FU; 5-Fluorouracil,Antimetabolite (DNA & RNA)
968,,,,,,,968,GLS,inhibitor of glutaminase,968,GLS
a-443654,,,A-443654,KIN001-139,AKT1; AKT2; AKT3,PI3K/MTOR signaling,,,,A-443654; KIN001-139,AKT2; AKT1; AKT3
a-770041,,,A-770041,KIN001-111,LCK; FYN,"Other, kinases",,,,KIN001-111; A-770041,FYN; LCK
a-804598,,,,,,,A-804598,P2RX7,inhibitor of purinergic receptor P2X,A-804598,P2RX7
aa-cocf3,,,,,,,AA-COCF3,FAAH; PLA2G4A; PLA2G4B; PLA2G4C; PLA2G4D,inhibitor of cytosolic phospholipase A2; inhibitor of fatty acid amide hydrolase,AA-COCF3,PLA2G4A; FAAH; PLA2G4C; PLA2G4D; PLA2G4B
abiraterone,,,,,,,abiraterone,CYP17A1,"inhibitor of 17 alpha-hydroxylase and C17,20 lyase",abiraterone,CYP17A1
abt-199,,,,,,,ABT-199,BCL2,inhibitor of BCL2,ABT-199,BCL2
abt-737,,,,,,,ABT-737,BCL2; BCL2L1; BCL2L2,"inhibitor of BCL2, BCL-xL, and BCL-W",ABT-737,BCL2; BCL2L2; BCL2L1
ac55649,,,,,,,AC55649,RARB,agonist of retinoic acid receptor beta,AC55649,RARB
aew541,AEW541,IGF1R,,,,,,,,AEW541,IGF1R
afatinib,,,Afatinib,"BIBW2992, Tovok, Gilotrif",ERBB2; EGFR,EGFR signaling,afatinib,EGFR; ERBB2,inhibitor of EGFR and HER2,Gilotrif; Afatinib; Tovok; BIBW2992; afatinib,ERBB2; EGFR
agk-2,,,,,,,AGK-2,SIRT2,inhibitor of sirtuin 2,AGK-2,SIRT2
aica ribonucleotide,,,AICA Ribonucleotide,"AICAR, N1-(b-D-Ribofuranosyl)-5-aminoimidazole-4-carboxamide",AMPK agonist,Metabolism,,,,AICA Ribonucleotide; N1-(b-D-Ribofuranosyl)-5-aminoimidazole-4-carboxamide; AICAR,AMPK agonist
akt inhibitor viii,,,AKT inhibitor VIII,Akti-1/2,AKT1; AKT2; AKT3,PI3K/MTOR signaling,,,,Akti-1/2; AKT inhibitor VIII,AKT2; AKT1; AKT3
alectinib,,,Alectinib,"CH5424802, CH 542802, Alecensa",ALK,RTK signaling,,,,CH5424802; Alectinib; Alecensa; CH 542802,ALK
alisertib,,,,,,,alisertib,AURKA; AURKB,inhibitor of aurora kinases A and B,alisertib,AURKA; AURKB
alisertib:navitoclax (2:1 mol/mol),,,,,,,alisertib:navitoclax (2:1 mol/mol),AURKA; AURKB; BCL2; BCL2L1; BCL2L2,"inhibitor of aurora kinases A and B;inhibitor of BCL2, BCL-xL, and BCL-W",alisertib:navitoclax (2:1 mol/mol),BCL2; BCL2L2; BCL2L1; AURKA; AURKB
alvocidib,,,,,,,alvocidib,CDK1; CDK2; CDK4; CDK6,inhibitor of cyclin-dependent kinases,alvocidib,CDK1; CDK4; CDK6; CDK2
am-580,,,,,,,AM-580,RARA,agonist of retinoic acid receptor alpha,AM-580,RARA
amuvatinib,,,Amuvatinib,"MP470, MP 470, MP-470",KIT; PDGFRA; FLT3,"Other, kinases",,,,MP470; MP-470; MP 470; Amuvatinib,PDGFRA; KIT; FLT3
apicidin,,,,,,,apicidin,HDAC1; HDAC2; HDAC3; HDAC6; HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8",apicidin,HDAC8; HDAC1; HDAC3; HDAC2; HDAC6
ar-42,,,AR-42,"HDAC-42, AR 42, AR42",HDAC1,Chromatin histone acetylation,,,,HDAC-42; AR 42; AR-42; AR42,HDAC1
as601245,,,AS601245,,JNK1; JNK2; JNK2,JNK and p38 signaling,,,,AS601245,JNK1; JNK2
as605240,,,AS605240,"KIN001-173, AS-605240",PI3Kgamma,PI3K/MTOR signaling,,,,AS605240; KIN001-173; AS-605240,PI3Kgamma
at-406,,,,,,,AT-406,XIAP,SMAC mimetic; inhibitor of inhibitor of apoptosis proteins (IAPs),AT-406,XIAP
at-7519,,,AT-7519,AT7519,CDK1; CDK2; CDK4; CDK6; CDK9,Cell cycle,,,,AT-7519; AT7519,CDK4; CDK1; CDK2; CDK9; CDK6
at13387,,,,,,,AT13387,HSP90AA1,inhibitor of HSP90,AT13387,HSP90AA1
at7867,,,,,,,AT7867,AKT1; AKT2; AKT3; RPS6KB2,inhibitor of AKT1/2/3 and S6K,AT7867,AKT2; AKT1; RPS6KB2; AKT3
austocystin d,,,,,,,austocystin D,,natural product; inducer of DNA damage,austocystin D,NaN
avagacestat,,,Avagacestat,"BMS-708163, BMS 708163",Amyloid beta20; Amyloid beta40,Other,,,,BMS 708163; BMS-708163; Avagacestat,Amyloid beta20; Amyloid beta40
avicin d,,,,,,,avicin D,,natural product,avicin D,NaN
avrainvillamide,,,,,,,avrainvillamide,NPM1,natural product; inhibitor of nucleophosmin,avrainvillamide,NPM1
axitinib,,,Axitinib,"AG-13736, Inlyta",PDGFR; KIT; VEGFR,RTK signaling,axitinib,FLT1; FLT3; KDR; KIT; PDGFRA; PDGFRB,"inhibitor of VEGFRs, c-KIT, and PDGFR alpha and beta",Inlyta; AG-13736; Axitinib; axitinib,KDR; PDGFRB; PDGFRA; PDGFR; VEGFR; KIT; FLT1; FLT3
az-3146,,,,,,,AZ-3146,TTK,inhibitor of TTK protein kinase,AZ-3146,TTK
az628,,,AZ628,"AZ-628, AZ 628",BRAF,ERK MAPK signaling,,,,AZ-628; AZ628; AZ 628,BRAF
azacitidine,,,,,,,azacitidine,DNMT1,inhibitor of DNA methyltransferase,azacitidine,DNMT1
azd1480,,,,,,,AZD1480,JAK1; JAK2,inhibitor of Janus kinases 1 and 2,AZD1480,JAK2; JAK1
azd4547,,,,,,,AZD4547,FGFR1; FGFR2; FGFR3,inhibitor of fibroblast growth factor receptors,AZD4547,FGFR2; FGFR1; FGFR3
azd6482,,,AZD6482,"AZD 6482, AZD-6482, AK-55409",PI3Kbeta,PI3K/MTOR signaling,AZD6482,PIK3CB; PIK3CD,inhibitor of PI3K catalytic subunits beta and delta,AZD-6482; AZD6482; AK-55409; AZD 6482,PIK3CB; PIK3CD; PI3Kbeta
azd7545,,,,,,,AZD7545,PDK2,inhibitor of pyruvate dehydrogenase kinase 2,AZD7545,PDK2
azd7762,,,AZD7762,"AZD-7762, AZD 7762",CHEK1; CHEK2,Cell cycle,AZD7762,CHEK1; CHEK2,inhibitor of checkpoint kinases 1 and 2,AZD 7762; AZD7762; AZD-7762,CHEK2; CHEK1
azd8055,,,AZD8055,AZD-8055,MTORC1; MTORC2,PI3K/MTOR signaling,AZD8055,MTOR,inhibitor of mTOR,AZD-8055; AZD8055,MTORC2; MTORC1; MTOR
b02,,,,,,,B02,RAD51,inhibitor of RAD51,B02,RAD51
bafilomycin a1,,,,,,,bafilomycin A1,ATP6V0A1,inhibitor of the vacuolar-type H+-ATPase,bafilomycin A1,ATP6V0A1
barasertib,,,,,,,barasertib,AURKB,inhibitor of aurora kinase B,barasertib,AURKB
bardoxolone methyl,,,,,,,bardoxolone methyl,,electrophilic inducer of the NFE2L2-KEAP1 pathway,bardoxolone methyl,NaN
bax channel blocker,,,,,,,Bax channel blocker,BAX,inhibitor of BAX-mediated mitochondrial cytochrome c release,Bax channel blocker,BAX
bay-61-3606,,,BAY-61-3606,"Syk Inhibitor, BAY-613606",SYK,"Other, kinases",,,,Syk Inhibitor; BAY-613606; BAY-61-3606,SYK
bcl-lzh-4,,,,,,,BCL-LZH-4,,"inhibitor of BCL2, BCL-xL, and MCL1",BCL-LZH-4,NaN
bec,,,,,,,BEC,ARG1; ARG2,inhibitor of arginase I and II,BEC,ARG1; ARG2
belinostat,,,Belinostat,"PXD101, PXD-101",HDAC1,Chromatin histone acetylation,belinostat,HDAC1; HDAC2; HDAC3; HDAC6; HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8",Belinostat; PXD101; PXD-101; belinostat,HDAC8; HDAC1; HDAC3; HDAC2; HDAC6
bendamustine,,,,,,,bendamustine,,DNA alkylator,bendamustine,NaN
betulinic acid,,,,,,,betulinic acid,,natural product; inhibitor of specificity protein 1 transcription factor in cells,betulinic acid,NaN
bexarotene,,,Bexarotene,"LG-100069, Targretin, Targret, Targrexin, Targretyn, Bexarotenum",Retinioic X receptor (RXR) agonist,Other,bexarotene,RXRA; RXRB; RXRG,inhibitor of retinoid X receptors,Targrexin; Bexarotene; Targretin; LG-100069; Bexarotenum; bexarotene; Targretyn; Targret,RXRG; Retinioic X receptor (RXR) agonist; RXRA; RXRB
bi-2536,,,BI-2536,,PLK1; PLK2; PLK3,Cell cycle,BI-2536,PLK1,inhibitor of polo-like kinase 1 (PLK1),BI-2536,PLK1; PLK3; PLK2
bibr-1532,,,,,,,BIBR-1532,TERT,inhibitor of telomerase reverse transcriptase,BIBR-1532,TERT
bicalutamide,,,Bicalutamide,"ICI-176334, Casodex, Cosudex, ICI 176334",AR,Hormone-related,,,,Casodex; ICI-176334; ICI 176334; Bicalutamide; Cosudex,AR
birinapant,,,,,,,birinapant,DIABLO; XIAP,SMAC mimetic; inhibitor of inhibitor of apoptosis proteins (IAPs),birinapant,DIABLO; XIAP
bix-01294,,,,,,,BIX-01294,EHMT2,inhibitor of G9a histone methyltransferase,BIX-01294,EHMT2
bix02189,,,BIX02189,BIX 02189,MEK5; ERK5,ERK MAPK signaling,,,,BIX02189; BIX 02189,ERK5; MEK5
blebbistatin,,,,,,,blebbistatin,MYH1; MYH2,inhibitor of myosin II ATPases,blebbistatin,MYH1; MYH2
bleomycin,,,Bleomycin,,dsDNA break induction,DNA replication,,,,Bleomycin,dsDNA break induction
bleomycin (50 um),,,Bleomycin (50 uM),,dsDNA break induction,DNA replication,,,,Bleomycin (50 uM),dsDNA break induction
bleomycin a2,,,,,,,bleomycin A2,,inducer of DNA damage,bleomycin A2,NaN
bms-195614,,,,,,,BMS-195614,RARA; RARB; RARG,antagonist of retinoic acid receptors,BMS-195614,RARG; RARA; RARB
bms-270394,,,,,,,BMS-270394,RARG,antagonist of retinoic acid receptor gamma,BMS-270394,RARG
bms-345541,,,BMS-345541,"BMS345541, IKK Inhibitor 3",IKK1; IKK2,"Other, kinases",BMS-345541,IKBKB,inhibitor of IKK-2,BMS-345541; BMS345541; IKK Inhibitor 3,IKK1; IKK2; IKBKB
bms-509744,,,BMS-509744,"KIN001-127, ITK inhibitor",ITK,Other,,,,ITK inhibitor; BMS-509744; KIN001-127,ITK
bms-536924,,,BMS-536924,BMS 536924,IGF1R; IR,IGFR signaling,BMS-536924,IGF1R; INSR,inhibitor of insulin-like growth factor 1 receptor (IGF1R) and insulin receptor (INSR),BMS 536924; BMS-536924,IR; INSR; IGF1R
bms-754807,,,BMS-754807,"BMS754807, BMS 754807",IGF1R; IR,IGFR signaling,BMS-754807,IGF1R,inhibitor of insulin-like growth factor 1 receptor and insulin receptor,BMS-754807; BMS754807; BMS 754807,IR; IGF1R
bortezomib,,,Bortezomib,"PS-341, LDP-341, Velcade",Proteasome,Protein stability and degradation,bortezomib,PSMB1; PSMB2; PSMB5; PSMD1; PSMD2,inhibitor of 26S proteasome,LDP-341; bortezomib; Velcade; PS-341; Bortezomib,PSMB5; PSMD2; PSMB2; PSMD1; PSMB1; Proteasome
bosutinib,,,Bosutinib,"SKI-606, Bosulif",SRC; ABL; TEC,"Other, kinases",bosutinib,ABL1; SRC,inhibitor of SRC and ABL1,Bosulif; Bosutinib; SKI-606; bosutinib,ABL; TEC; SRC; ABL1
brd-a02303741,,,,,,,BRD-A02303741,DOT1L,inhibitor of histone methyltransferases,BRD-A02303741,DOT1L
brd-a02303741:carboplatin (1:1 mol/mol),,,,,,,BRD-A02303741:carboplatin (1:1 mol/mol),DOT1L,inhibitor of histone methyltransferases;inducer of DNA damage,BRD-A02303741:carboplatin (1:1 mol/mol),DOT1L
brd-a02303741:navitoclax (2:1 mol/mol),,,,,,,BRD-A02303741:navitoclax (2:1 mol/mol),DOT1L; BCL2; BCL2L1; BCL2L2,"inhibitor of histone methyltransferases;inhibitor of BCL2, BCL-xL, and BCL-W",BRD-A02303741:navitoclax (2:1 mol/mol),BCL2; BCL2L2; BCL2L1; DOT1L
brd-a05715709,,,,,,,BRD-A05715709,IDH1,putative inhibitor of IDH1 R132H,BRD-A05715709,IDH1
brd-a71883111,,,,,,,BRD-A71883111,IDH1,putative inhibitor of IDH1 R132H,BRD-A71883111,IDH1
brd-a86708339,,,,,,,BRD-A86708339,,screening hit,BRD-A86708339,NaN
brd-a94377914,,,,,,,BRD-A94377914,HDAC1; HDAC2; HDAC3; HDAC6; HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8",BRD-A94377914,HDAC8; HDAC1; HDAC3; HDAC2; HDAC6
brd-k01737880,,,,,,,BRD-K01737880,,screening hit,BRD-K01737880,NaN
brd-k02251932,,,,,,,BRD-K02251932,,product of diversity oriented synthesis,BRD-K02251932,NaN
brd-k02492147,,,,,,,BRD-K02492147,,product of diversity oriented synthesis,BRD-K02492147,NaN
brd-k03536150,,,,,,,BRD-K03536150,BAX,activator of BAX,BRD-K03536150,BAX
brd-k03911514,,,,,,,BRD-K03911514,,stapled helical peptide,BRD-K03911514,NaN
brd-k04800985,,,,,,,BRD-K04800985,,product of diversity oriented synthesis,BRD-K04800985,NaN
brd-k07442505,,,,,,,BRD-K07442505,BAX,stapled helical peptide activating BAX,BRD-K07442505,BAX
brd-k09344309,,,,,,,BRD-K09344309,,screening hit,BRD-K09344309,NaN
brd-k09587429,,,,,,,BRD-K09587429,,product of diversity oriented synthesis,BRD-K09587429,NaN
brd-k11533227,,,,,,,BRD-K11533227,HDAC1; HDAC2,inhibitor of HDAC1 and HDAC2,BRD-K11533227,HDAC1; HDAC2
brd-k13185470,,,,,,,BRD-K13185470,MCL1,stapled helical peptide targeting MCL1,BRD-K13185470,MCL1
brd-k13999467,,,,,,,BRD-K13999467,,product of diversity oriented synthesis,BRD-K13999467,NaN
brd-k14844214,,,,,,,BRD-K14844214,,product of diversity oriented synthesis,BRD-K14844214,NaN
brd-k16130065,,,,,,,BRD-K16130065,,stapled helical peptide,BRD-K16130065,NaN
brd-k16147474,,,,,,,BRD-K16147474,,product of diversity oriented synthesis,BRD-K16147474,NaN
brd-k17060750,,,,,,,BRD-K17060750,,product of diversity oriented synthesis,BRD-K17060750,NaN
brd-k19103580,,,,,,,BRD-K19103580,,product of diversity oriented synthesis,BRD-K19103580,NaN
brd-k20514654,,,,,,,BRD-K20514654,,stapled helical peptide,BRD-K20514654,NaN
brd-k24690302,,,,,,,BRD-K24690302,HDAC1,inhibitor of HDAC1,BRD-K24690302,HDAC1
brd-k26531177,,,,,,,BRD-K26531177,,analog of the natural product piperlongumine,BRD-K26531177,NaN
brd-k27188169,,,,,,,BRD-K27188169,,stapled helical peptide,BRD-K27188169,NaN
brd-k27188169:navitoclax (2:1 mol/mol),,,,,,,BRD-K27188169:navitoclax (2:1 mol/mol),BCL2; BCL2L1; BCL2L2,"stapled helical peptide;inhibitor of BCL2, BCL-xL, and BCL-W",BRD-K27188169:navitoclax (2:1 mol/mol),BCL2; BCL2L2; BCL2L1
brd-k27224038,,,,,,,BRD-K27224038,,product of diversity oriented synthesis,BRD-K27224038,NaN
brd-k27986637,,,,,,,BRD-K27986637,,product of diversity oriented synthesis; screening hit,BRD-K27986637,NaN
brd-k28456706,,,,,,,BRD-K28456706,HNF4A,inhibitor of hepatocyte nuclear factor 4 alpha,BRD-K28456706,HNF4A
brd-k29086754,,,,,,,BRD-K29086754,,product of diversity oriented synthesis,BRD-K29086754,NaN
brd-k29313308,,,,,,,BRD-K29313308,HDAC3,inhibitor of HDAC3,BRD-K29313308,HDAC3
brd-k30019337,,,,,,,BRD-K30019337,,product of diversity oriented synthesis,BRD-K30019337,NaN
brd-k30748066,,,,,,,BRD-K30748066,CDK9,inhibitor of CDK9,BRD-K30748066,CDK9
brd-k33199242,,,,,,,BRD-K33199242,,product of diversity oriented synthesis,BRD-K33199242,NaN
brd-k33514849,,,,,,,BRD-K33514849,,screening hit,BRD-K33514849,NaN
brd-k34099515,,,,,,,BRD-K34099515,,screening hit,BRD-K34099515,NaN
brd-k34222889,,,,,,,BRD-K34222889,,analog of the natural product piperlongumine,BRD-K34222889,NaN
brd-k34485477,,,,,,,BRD-K34485477,,product of diversity oriented synthesis,BRD-K34485477,NaN
brd-k35604418,,,,,,,BRD-K35604418,MCL1,inhibitor of MCL1,BRD-K35604418,MCL1
brd-k37390332,,,,,,,BRD-K37390332,,product of diversity oriented synthesis,BRD-K37390332,NaN
brd-k41334119,,,,,,,BRD-K41334119,,product of diversity oriented synthesis,BRD-K41334119,NaN
brd-k41597374,,,,,,,BRD-K41597374,,product of diversity oriented synthesis,BRD-K41597374,NaN
brd-k42260513,,,,,,,BRD-K42260513,EZH2,inhibitor of enhancer of zeste polycomb repressive complex 2 subunit,BRD-K42260513,EZH2
brd-k44224150,,,,,,,BRD-K44224150,,product of diversity oriented synthesis,BRD-K44224150,NaN
brd-k45681478,,,,,,,BRD-K45681478,,product of diversity oriented synthesis; screening hit,BRD-K45681478,NaN
brd-k48334597,,,,,,,BRD-K48334597,,product of diversity oriented synthesis,BRD-K48334597,NaN
brd-k48477130,,,,,,,BRD-K48477130,,screening hit,BRD-K48477130,NaN
brd-k49290616,,,,,,,BRD-K49290616,,product of diversity oriented synthesis,BRD-K49290616,NaN
brd-k50799972,,,,,,,BRD-K50799972,,product of diversity oriented synthesis,BRD-K50799972,NaN
brd-k51490254,,,,,,,BRD-K51490254,HDAC6; HDAC8,inhibitor of HDAC6 and HDAC8,BRD-K51490254,HDAC8; HDAC6
brd-k51831558,,,,,,,BRD-K51831558,EZH2,inhibitor of enhancer of zeste polycomb repressive complex 2 subunit,BRD-K51831558,EZH2
brd-k52037352,,,,,,,BRD-K52037352,,product of diversity oriented synthesis,BRD-K52037352,NaN
brd-k55116708,,,,,,,BRD-K55116708,,product of diversity oriented synthesis; inhibitor of leukemic stem cells,BRD-K55116708,NaN
brd-k55473186,,,,,,,BRD-K55473186,NOTCH1,stapled helical peptide targeting NOTCH1,BRD-K55473186,NOTCH1
brd-k58730230,,,,,,,BRD-K58730230,,stapled helical peptide,BRD-K58730230,NaN
brd-k61166597,,,,,,,BRD-K61166597,,inhibitor of HDAC1 and HDAC2,BRD-K61166597,NaN
brd-k63431240,,,,,,,BRD-K63431240,,product of diversity oriented synthesis; screening hit,BRD-K63431240,NaN
brd-k64610608,,,,,,,BRD-K64610608,,product of diversity oriented synthesis; screening hit,BRD-K64610608,NaN
brd-k66453893,,,,,,,BRD-K66453893,,product of diversity oriented synthesis,BRD-K66453893,NaN
brd-k66532283,,,,,,,BRD-K66532283,HDAC1; HDAC2,inhibitor of HDAC1 and HDAC2,BRD-K66532283,HDAC1; HDAC2
brd-k70511574,,,,,,,BRD-K70511574,PLK1,inhibitor of polo-like kinase 1 (PLK1),BRD-K70511574,PLK1
brd-k71781559,,,,,,,BRD-K71781559,,screening hit,BRD-K71781559,NaN
brd-k71935468,,,,,,,BRD-K71935468,,inducer of ROS,BRD-K71935468,NaN
brd-k75293299,,,,,,,BRD-K75293299,,product of diversity oriented synthesis,BRD-K75293299,NaN
brd-k78574327,,,,,,,BRD-K78574327,,product of diversity oriented synthesis,BRD-K78574327,NaN
brd-k79669418,,,,,,,BRD-K79669418,MDM2; MDM4,inhibitor of MDM4-p53 interaction,BRD-K79669418,MDM2; MDM4
brd-k80183349,,,,,,,BRD-K80183349,HDAC1; HDAC2,inhibitor of HDAC1 and HDAC2,BRD-K80183349,HDAC1; HDAC2
brd-k84807411,,,,,,,BRD-K84807411,,product of diversity oriented synthesis,BRD-K84807411,NaN
brd-k85133207,,,,,,,BRD-K85133207,HDAC1,inhibitor of HDAC1,BRD-K85133207,HDAC1
brd-k86535717,,,,,,,BRD-K86535717,,product of diversity oriented synthesis,BRD-K86535717,NaN
brd-k88742110,,,,,,,BRD-K88742110,HDAC8,inhibitor of HDAC8,BRD-K88742110,HDAC8
brd-k90370028,,,,,,,BRD-K90370028,,screening hit,BRD-K90370028,NaN
brd-k92856060,,,,,,,BRD-K92856060,,screening hit,BRD-K92856060,NaN
brd-k94991378,,,,,,,BRD-K94991378,,inducer of ROS,BRD-K94991378,NaN
brd-k96431673,,,,,,,BRD-K96431673,,product of diversity oriented synthesis,BRD-K96431673,NaN
brd-k96970199,,,,,,,BRD-K96970199,,product of diversity oriented synthesis,BRD-K96970199,NaN
brd-k97651142,,,,,,,BRD-K97651142,,aphrocallistin derivative,BRD-K97651142,NaN
brd-k99006945,,,,,,,BRD-K99006945,,screening hit,BRD-K99006945,NaN
brd-k99584050,,,,,,,BRD-K99584050,,stapled helical peptide,BRD-K99584050,NaN
brd-m00053801,,,,,,,BRD-M00053801,BCL2,inhibitor of BCL2,BRD-M00053801,BCL2
brd1812,,,,,,,BRD1812,,screening hit,BRD1812,NaN
brd1835,,,,,,,BRD1835,EZH2,product of diversity oriented synthesis; screening hit,BRD1835,EZH2
brd4132,,,,,,,BRD4132,,screening hit,BRD4132,NaN
brd6340,,,,,,,BRD6340,,screening hit,BRD6340,NaN
brd8899,,,,,,,BRD8899,STK33,inhibitor of serine/threonine kinasase STK33,BRD8899,STK33
brd8958,,,,,,,BRD8958,EP300,inhibitor of E1A binding protein p300,BRD8958,EP300
brd9647,,,,,,,BRD9647,,screening hit,BRD9647,NaN
brd9876,,,,,,,BRD9876,,screening hit,BRD9876,NaN
brd9876:mk-1775 (4:1 mol/mol),,,,,,,BRD9876:MK-1775 (4:1 mol/mol),WEE1,screening hit;inhibitor of WEE1,BRD9876:MK-1775 (4:1 mol/mol),WEE1
brefeldin a,,,,,,,brefeldin A,ARF1,modulator of ADP-ribosylation factor 1; inhibitor of protein translocation from ER to Golgi,brefeldin A,ARF1
brivanib,,,,,,,brivanib,FLT1; KDR,inhibitor of VEGFR 1/2,brivanib,FLT1; KDR
bryostatin 1,,,Bryostatin 1,Bryostatin,PKC,"Other, kinases",,,,Bryostatin; Bryostatin 1,PKC
bx-912,,,BX-912,,PDK1 (PDPK1),PI3K/MTOR signaling,,,,BX-912,PDK1 (PDPK1)
bx795,,,BX795,BX-795,TBK1; PDK1 (PDPK1); IKK; AURKB; AURKC,Other,,,,BX795; BX-795,PDK1 (PDPK1); AURKC; IKK; TBK1; AURKB
byl-719,,,,,,,BYL-719,PIK3CA,inhibitor of PI3K catalytic subunit alpha,BYL-719,PIK3CA
c6-ceramide,,,,,,,C6-ceramide,MAPK1; PPP2CA; UGCG,inhibitor of glucosylceramide synthase; activator of MAP kinase (ERK); stimulator of protein phosphatase 2A,C6-ceramide,UGCG; PPP2CA; MAPK1
cabozantinib,,,Cabozantinib,"BMS-907351, XL-184, Cometriq","VEGFR; MET; RET; KIT; FLT1; FLT3; FLT4; TIE2,AXL","Other, kinases",cabozantinib,FLT3; KDR; MET; RET,"inhibitor of c-MET, VEGFR2/3, and RET",BMS-907351; Cabozantinib; XL-184; cabozantinib; Cometriq,"TIE2,AXL; KDR; FLT4; VEGFR; RET; KIT; MET; FLT1; FLT3"
camptothecin,,,Camptothecin,"Camptothecine, (+)-Camptothecin",TOP1,DNA replication,,,,(+)-Camptothecin; Camptothecin; Camptothecine,TOP1
canertinib,,,,,,,canertinib,EGFR; ERBB2,inhibitor of EGFR and HER2,canertinib,EGFR; ERBB2
carboplatin,,,,,,,carboplatin,,inducer of DNA damage,carboplatin,NaN
carboplatin:etoposide (40:17 mol/mol),,,,,,,carboplatin:etoposide (40:17 mol/mol),TOP2A,inducer of DNA damage;inhibitor of topoisomerase II,carboplatin:etoposide (40:17 mol/mol),TOP2A
carboplatin:unc0638 (2:1 mol/mol),,,,,,,carboplatin:UNC0638 (2:1 mol/mol),EHMT1; EHMT2,inducer of DNA damage;inhibitor of EHMT2 and GLP methyltransferase,carboplatin:UNC0638 (2:1 mol/mol),EHMT1; EHMT2
cay10576,,,,,,,CAY10576,IKBKE,inhibitor of IKK-epsilon,CAY10576,IKBKE
cay10594,,,,,,,CAY10594,PLD2,inhibitor of phospholipase D2,CAY10594,PLD2
cay10603,,,CAY10603,,HDAC1; HDAC6,Chromatin histone acetylation,,,,CAY10603,HDAC1; HDAC6
cay10618,,,,,,,CAY10618,NAMPT,inhibitor of nicotinamide phosphoribosyltransferase,CAY10618,NAMPT
cbb-1007,,,,,,,CBB-1007,KDM1A,inhibitor of lysine-specific demethylase 1A (LSD1),CBB-1007,KDM1A
cct-018159,,,CCT-018159,"CCT018159, CCT 018159",HSP90,Protein stability and degradation,,,,CCT 018159; CCT018159; CCT-018159,HSP90
cct007093,,,CCT007093,,PPM1D,Other,,,,CCT007093,PPM1D
cct036477,,,,,,,CCT036477,,inhibitor of WNT signaling by blocking beta-catenin transcription,CCT036477,NaN
cd-1530,,,,,,,CD-1530,RARG,agonist of retinoic acid receptor gamma,CD-1530,RARG
cd-437,,,,,,,CD-437,RARG,agonist of retinoic acid receptor gamma,CD-437,RARG
cediranib,,,,,,,cediranib,FLT1; FLT4; KDR,inhibitor of VEGFRs,cediranib,FLT1; KDR; FLT4
ceranib-2,,,,,,,ceranib-2,ACER1; ACER2; ACER3; ASAH1; ASAH2; ASAH2B,inhibitor of ceramidase activity,ceranib-2,ACER2; ACER1; ASAH2; ASAH1; ASAH2B; ACER3
cerulenin,,,,,,,cerulenin,FASN; HMGCS1,inhibitor of fatty acid synthase; inhibitor of HMG-CoA synthase,cerulenin,FASN; HMGCS1
cetuximab,,,Cetuximab,"Erbitux, IMC-C225, C225, IMC-225, L01XC06",EGFR,EGFR signaling,,,,C225; L01XC06; Erbitux; IMC-225; Cetuximab; IMC-C225,EGFR
cgp-082996,,,CGP-082996,"CINK4, KIN001-021",CDK4,Cell cycle,,,,KIN001-021; CGP-082996; CINK4,CDK4
cgp-60474,,,CGP-60474,"KIN001-019, CGP60474, CGP 60474","CDK1,CDK2,CDK5,CDK7,CDK9; PKC",Cell cycle,,,,CGP 60474; CGP60474; CGP-60474; KIN001-019,"PKC; CDK1,CDK2,CDK5,CDK7,CDK9"
ch-55,,,,,,,Ch-55,RARA; RARB; RARG,agonist of retinoid acid receptors,Ch-55,RARG; RARA; RARB
chir-99021,,,CHIR-99021,"CT 99021, CHIR99021, CHIR 99021",GSK3A; GSK3B,WNT signaling,CHIR-99021,GSK3B,inhibitor of GSK3 beta,CHIR99021; CT 99021; CHIR 99021; CHIR-99021,GSK3B; GSK3A
chlorambucil,,,,,,,chlorambucil,,DNA alkylator,chlorambucil,NaN
chm-1,,,,,,,CHM-1,,inhibitor of tubulin polymerization,CHM-1,NaN
ci-1040,,,CI-1040,"CI 1040, PD-18435, PD-184352, 212631-79-3",MEK1; MEK2,ERK MAPK signaling,,,,PD-18435; CI 1040; PD-184352; CI-1040; 212631-79-3,MEK1; MEK2
ci-976,,,,,,,CI-976,ACAT1,inhibitor of acetyl-CoA acetyltransferase I,CI-976,ACAT1
ciclopirox,,,,,,,ciclopirox,RRM1,substituted pyridone antimycotic; inhibitor of the iron-dependent enzyme ribonucleotide reductase,ciclopirox,RRM1
ciclosporin,,,,,,,ciclosporin,PPID,inhibitor of calcineurin by binding to cyclophilin D,ciclosporin,PPID
cid-5951923,,,,,,,CID-5951923,KLF5,modulator of KLF5 expression,CID-5951923,KLF5
cil41,,,,,,,CIL41,,screening hit,CIL41,NaN
cil55,,,,,,,CIL55,,screening hit,CIL55,NaN
cil55a,,,,,,,CIL55A,,screening hit,CIL55A,NaN
cil56,,,,,,,CIL56,,screening hit,CIL56,NaN
cil70,,,,,,,CIL70,,screening hit,CIL70,NaN
cimetidine,,,,,,,cimetidine,HRH2,inhibitor of histidine receptor H2,cimetidine,HRH2
cisplatin,,,Cisplatin,"cis-Diammineplatinum(II) dichloride, Platinol, CIS-DDP",DNA crosslinker,DNA replication,,,,CIS-DDP; Cisplatin; Platinol; cis-Diammineplatinum(II) dichloride,DNA crosslinker
clofarabine,,,,,,,clofarabine,,inducer of DNA damage,clofarabine,NaN
cmk,,,CMK,KIN001-128,RSK2,ERK MAPK signaling,,,,CMK; KIN001-128,RSK2
col-3,,,,,,,COL-3,,analog of tetracycline,COL-3,NaN
compound 1541a,,,,,,,Compound 1541A,CASP3; CASP6; CASP7,"activators of executioner procaspases 3, 6, and 7",Compound 1541A,CASP6; CASP7; CASP3
compound 1b,,,,,,,compound 1B,,screening hit,compound 1B,NaN
compound 23 citrate,,,,,,,Compound 23 citrate,,analog of natural product cortistatin,Compound 23 citrate,NaN
compound 7d-cis,,,,,,,Compound 7d-cis,XPO1,inhibitor of CRM1-mediated nucleocytoplasmic transport,Compound 7d-cis,XPO1
cp466722,,,CP466722,"CP-466722, CP 466722, 1080622-86-1",ATM,Genome integrity,,,,CP466722; CP 466722; 1080622-86-1; CP-466722,ATM
cp724714,,,CP724714,CP-724714,ERBB2,EGFR signaling,,,,CP-724714; CP724714,ERBB2
cr-1-31b,,,,,,,CR-1-31B,EIF4A2; EIF4E; EIF4G1,silvestrol analog; inhibits translation by modulating the eIF4F complex,CR-1-31B,EIF4E; EIF4G1; EIF4A2
crizotinib,PF2341066,c-MET,Crizotinib,"Xalkori, PF2341066, PF-2341066, PF 2341066",MET; ALK; ROS1,RTK signaling,crizotinib,ALK; MET,inhibitor of c-MET and ALK,Crizotinib; PF-2341066; Xalkori; PF 2341066; PF2341066; crizotinib,ALK; ROS1; c-MET; MET
crizotinib:plx-4032 (2:1 mol/mol),,,,,,,crizotinib:PLX-4032 (2:1 mol/mol),ALK; MET; BRAF,inhibitor of c-MET and ALK;inhibitor of BRAF,crizotinib:PLX-4032 (2:1 mol/mol),ALK; BRAF; MET
cucurbitacin i,,,,,,,cucurbitacin I,,natural product; modulator of NFKB1 and STAT3 signaling,cucurbitacin I,NaN
cudc-101,,,CUDC-101,CUDC 101,HDAC1-10; EGFR; ERBB2,Other,,,,CUDC-101; CUDC 101,EGFR; HDAC1-10; ERBB2
curcumin,,,,,,,curcumin,,natural product; modulator of ROS; modulator of NF-kappa-B signaling,curcumin,NaN
cx-5461,,,CX-5461,"CX5461, CX 5461",RNA Polymerase 1,Other,,,,CX5461; CX 5461; CX-5461,RNA Polymerase 1
cyanoquinoline 11,,,,,,,cyanoquinoline 11,MAP3K8,inhibitor of MAP3K8; inhibitor of phosphorylated EGFR in cells,cyanoquinoline 11,MAP3K8
cyclopamine,,,Cyclopamine,,SMO,Other,,,,Cyclopamine,SMO
cyclophosphamide,,,,,,,cyclophosphamide,,DNA alkylator,cyclophosphamide,NaN
cytarabine,,,Cytarabine,"Ara-Cytidine, Arabinosyl Cytosine, U-19920",Antimetabolite,DNA replication,,,,U-19920; Arabinosyl Cytosine; Ara-Cytidine; Cytarabine,Antimetabolite
cytarabine hydrochloride,,,,,,,cytarabine hydrochloride,,inducer of DNA damage,cytarabine hydrochloride,NaN
cytochalasin b,,,,,,,cytochalasin B,,inhibitor of actin polymerization,cytochalasin B,NaN
dabrafenib,,,Dabrafenib,"GSK2118436, Tafinlar",BRAF,ERK MAPK signaling,dabrafenib,BRAF,inhibitor of BRAF,Tafinlar; dabrafenib; GSK2118436; Dabrafenib,BRAF
dacarbazine,,,,,,,dacarbazine,,DNA alkylator,dacarbazine,NaN
dacinostat,,,Dacinostat,"NVP-LAQ824, LAQ824",HDAC1,Chromatin histone acetylation,,,,NVP-LAQ824; Dacinostat; LAQ824,HDAC1
dactolisib,,,Dactolisib,"NVP-BEZ235, BEZ235",PI3K (Class 1); MTORC1; MTORC2,PI3K/MTOR signaling,NVP-BEZ235,MTOR; PIK3CA; PIK3CB; PIK3CD; PIK3CG,inhibitor of PI3K and mTOR kinase activity,Dactolisib; NVP-BEZ235; BEZ235,PIK3CA; MTOR; MTORC2; MTORC1; PIK3CB; PIK3CG; PI3K (Class 1); PIK3CD
daporinad,,,Daporinad,"APO866,  FK866, FK866",NAMPT ,Metabolism,daporinad,NAMPT,inhibitor of nicotinamide phosphoribosyltransferase,daporinad;  FK866; APO866; FK866; Daporinad,NAMPT ; NAMPT
darinaparsin,,,,,,,darinaparsin,,inducer of ROS; inhibitor of microtubule assembly,darinaparsin,NaN
dasatinib,,,Dasatinib,"BMS-354825-03, BMS-354825, Sprycel",ABL; SRC; Ephrins; PDGFR; KIT,Other,dasatinib,EPHA2; KIT; LCK; SRC; YES1,"inhibitor of SRC, YES1, EPHA2, c-KIT, and LCK",BMS-354825-03; dasatinib; Sprycel; BMS-354825; Dasatinib,EPHA2; LCK; Ephrins; YES1; PDGFR; SRC; KIT; ABL
dbeq,,,,,,,DBeQ,VCP,inhibitor of p97 in cells,DBeQ,VCP
decitabine,,,,,,,decitabine,DNMT1,inhibitor of DNA methyltransferase,decitabine,DNMT1
decitabine:carboplatin (1:1 mol/mol),,,,,,,decitabine:carboplatin (1:1 mol/mol),DNMT1,inhibitor of DNA methyltransferase;inducer of DNA damage,decitabine:carboplatin (1:1 mol/mol),DNMT1
decitabine:navitoclax (2:1 mol/mol),,,,,,,decitabine:navitoclax (2:1 mol/mol),DNMT1; BCL2; BCL2L1; BCL2L2,"inhibitor of DNA methyltransferase;inhibitor of BCL2, BCL-xL, and BCL-W",decitabine:navitoclax (2:1 mol/mol),BCL2; BCL2L2; DNMT1; BCL2L1
dexamethasone,,,,,,,dexamethasone,NR3C1,agonist of glucocorticoid receptor,dexamethasone,NR3C1
dinaciclib,,,,,,,dinaciclib,CDK1; CDK2; CDK5; CDK9,inhibitor of cyclin-dependent kinases,dinaciclib,CDK1; CDK2; CDK9; CDK5
dmog,,,DMOG,Dimethyloxalylglcine,HIF-PH,Metabolism,,,,Dimethyloxalylglcine; DMOG,HIF-PH
docetaxel,,,Docetaxel,"RP-56976, Taxotere",Microtubule stabiliser,Mitosis,docetaxel,,inhibitor of microtubule assembly,Taxotere; docetaxel; RP-56976; Docetaxel,Microtubule stabiliser
docetaxel:tanespimycin (2:1 mol/mol),,,,,,,docetaxel:tanespimycin (2:1 mol/mol),HSP90AA1,inhibitor of microtubule assembly;inhibitor of HSP90,docetaxel:tanespimycin (2:1 mol/mol),HSP90AA1
doramapimod,,,Doramapimod,"BIRB-796, BIRB 796",p38; JNK2,JNK and p38 signaling,BIRB-796,MAPK11; MAPK11; MAPK14,inhibitor of p38 MAPK,BIRB 796; BIRB-796; Doramapimod,p38; JNK2; MAPK11; MAPK14
doxorubicin,,,Doxorubicin,"Doxil, Rubex, Adriamycin, Adriablastin, Doxorubicine",Anthracycline,DNA replication,doxorubicin,TOP2A,inhibitor of topoisomerase II,Doxil; Adriamycin; Doxorubicin; doxorubicin; Adriablastin; Doxorubicine; Rubex,TOP2A; Anthracycline
doxorubicin:navitoclax (2:1 mol/mol),,,,,,,doxorubicin:navitoclax (2:1 mol/mol),TOP2A; BCL2; BCL2L1; BCL2L2,"inhibitor of topoisomerase II;inhibitor of BCL2, BCL-xL, and BCL-W",doxorubicin:navitoclax (2:1 mol/mol),BCL2; BCL2L2; TOP2A; BCL2L1
eht-1864,,,EHT-1864,EHT 1864,RAC1; RAC2; RAC3,Cytoskeleton,,,,EHT 1864; EHT-1864,RAC1; RAC2; RAC3
elcpk,,,,,,,ELCPK,,screening hit,ELCPK,NaN
elesclomol,,,Elesclomol,STA-4783,HSP90,Protein stability and degradation,,,,STA-4783; Elesclomol,HSP90
elocalcitol,,,,,,,elocalcitol,VDR,agonist of vitamin D receptor,elocalcitol,VDR
embelin,,,Embelin,"Emberine, Embelic acid",XIAP,Apoptosis regulation,,,,Embelin; Emberine; Embelic acid,XIAP
entinostat,,,Entinostat,MS-275,HDAC1; HDAC3,Chromatin histone acetylation,entinostat,HDAC1; HDAC2; HDAC3; HDAC6; HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8",Entinostat; entinostat; MS-275,HDAC8; HDAC1; HDAC3; HDAC2; HDAC6
enzastaurin,,,Enzastaurin,LY317615,PKCB,"Other, kinases",,,,Enzastaurin; LY317615,PKCB
epigallocatechin-3-monogallate,,,,,,,epigallocatechin-3-monogallate,,natural product,epigallocatechin-3-monogallate,NaN
epothilone b,,,Epothilone B,"Patupilone, EpoB, EPO906, GNF-PF-193",Microtubule stabiliser,Mitosis,,,,Patupilone; EpoB; Epothilone B; EPO906; GNF-PF-193,Microtubule stabiliser
erastin,,,,,,,erastin,SLC7A11; VDAC1; VDAC2,modulator of voltage-dependent anion channels; inhibitor of solute carrier SLC7A11,erastin,VDAC2; VDAC1; SLC7A11
erismodegib,,,,,,,erismodegib,,screening hit,erismodegib,NaN
erlotinib,Erlotinib,EGFR,Erlotinib,"Tarceva, RG-1415, CP-358774, OSI-774, Ro-508231, R-1415",EGFR,EGFR signaling,erlotinib,EGFR; ERBB2,inhibitor of EGFR and HER2,Tarceva; CP-358774; RG-1415; erlotinib; Ro-508231; Erlotinib; R-1415; OSI-774,EGFR; ERBB2
erlotinib:plx-4032 (2:1 mol/mol),,,,,,,erlotinib:PLX-4032 (2:1 mol/mol),EGFR; ERBB2; BRAF,inhibitor of EGFR and HER2;inhibitor of BRAF,erlotinib:PLX-4032 (2:1 mol/mol),BRAF; EGFR; ERBB2
etomoxir,,,,,,,etomoxir,CPT1A,inhibitor of carnitine palmitoyltransferase,etomoxir,CPT1A
etoposide,,,Etoposide,"Etopophos, Vepesid, Eposin, VP-16",TOP2,DNA replication,etoposide,TOP2A,inhibitor of topoisomerase II,Etopophos; Vepesid; etoposide; VP-16; Etoposide; Eposin,TOP2A; TOP2
etp-46464,,,,,,,ETP-46464,ATM; ATR,inhibitor of serine/threonine-protein kinase ATR,ETP-46464,ATR; ATM
fedratinib,,,Fedratinib,"TG101348, TG-101348, SAR302503, SAR-302503",JAK2,"Other, kinases",TG-101348,JAK2,inhibitor of Janus kinase 2,TG101348; TG-101348; SAR302503; SAR-302503; Fedratinib,JAK2
fgin-1-27,,,,,,,FGIN-1-27,TSPO,activator of peripheral benzodiazepine receptor/translocator protein,FGIN-1-27,TSPO
fh535,,,FH535,,PPARgamma; PPARdelta,WNT signaling,,,,FH535,PPARdelta; PPARgamma
fingolimod,,,,,,,fingolimod,S1PR1,inhibitor of sphingosine 1-phosphate receptor,fingolimod,S1PR1
fluorouracil,,,,,,,fluorouracil,TYMS,pyrimidine analog; inhibitor of thymidylate synthase,fluorouracil,TYMS
fluvastatin,,,,,,,fluvastatin,HMGCR,inhibitor of HMG-CoA reductase,fluvastatin,HMGCR
fmk,,,FMK,KIN001-242,RSK,"Other, kinases",,,,FMK; KIN001-242,RSK
foretinib,,,Foretinib,"GSK1363089, XL-880, EXEL-2880, GSK089",MET; KDR; TIE2; VEGFR3/FLT4; RON; PDGFR; FGFR1; EGFR,RTK signaling,foretinib,KDR; MET,inhibitor of MET and VEGFR2,foretinib; XL-880; GSK089; EXEL-2880; GSK1363089; Foretinib,KDR; PDGFR; RON; FGFR1; EGFR; VEGFR3/FLT4; MET; TIE2
fqi-1,,,,,,,FQI-1,,inhibitor of LSF1-mediated transcription,FQI-1,NaN
fqi-2,,,,,,,FQI-2,,inhibitor of LSF1-mediated transcription,FQI-2,NaN
fr-180204,,,FR-180204,"FR 180204, FR180204, ERK Inhibitor II",ERK1; ERK2,ERK MAPK signaling,,,,FR180204; FR 180204; ERK Inhibitor II; FR-180204,ERK1; ERK2
fsc231,,,,,,,FSC231,PICK1,inhibitor of PDZ domain of protein interacting with PRKCA 1 (PICK1),FSC231,PICK1
fti-277,,,FTI-277,,Farnesyl-transferase (FNTA),Other,,,,FTI-277,Farnesyl-transferase (FNTA)
fulvestrant,,,,,,,fulvestrant,ESR1; GPER1,antagonist of the estrogen receptor,fulvestrant,ESR1; GPER1
fumonisin b1,,,,,,,fumonisin B1,CERS1; CERS2; CERS3; CERS4; CERS5; CERS6,inhibitor of ceramide synthase,fumonisin B1,CERS4; CERS5; CERS6; CERS3; CERS2; CERS1
gant-61,,,,,,,GANT-61,,inhibitor of hedgehog signaling pathway,GANT-61,NaN
gdc-0879,,,,,,,GDC-0879,BRAF,inhibitor of BRAF,GDC-0879,BRAF
gefitinib,,,Gefitinib,"ZD-1839, Iressa",EGFR,EGFR signaling,gefitinib,AKT1; EGFR,inhibitor of EGFR and AKT1,gefitinib; Gefitinib; Iressa; ZD-1839,AKT1; EGFR
gemcitabine,,,Gemcitabine,"Gemzar, LY-188011",Pyrimidine antimetabolite,DNA replication,gemcitabine,CMPK1; RRM1; TYMS,"inhibitor of DNA replication; inhibitor of ribonucleotide reductase, thymidylate synthetase, and cytidine monophosphate (UMP-CMP) kinase ",Gemcitabine; Gemzar; gemcitabine; LY-188011,CMPK1; TYMS; RRM1; Pyrimidine antimetabolite
genentech cpd 10,,,Genentech Cpd 10,,AURKA; AURKB,Mitosis,,,,Genentech Cpd 10,AURKA; AURKB
gmx-1778,,,,,,,GMX-1778,NAMPT,inhibitor of nicotinamide phosphoribosyltransferase,GMX-1778,NAMPT
gnf-2,,,GNF-2,KIN001-013,BCR-ABL,ABL signaling,,,,GNF-2; KIN001-013,BCR-ABL
gossypol,,,,,,,gossypol,BCL2; BCL2L1; LDHA; LDHB; LDHC,inhibitor of lactate dehydrogenase; inhibitor of BCL2 family members,gossypol,BCL2; BCL2L1; LDHC; LDHA; LDHB
gsk-3 inhibitor ix,,,,,,,GSK-3 inhibitor IX,,inhibitor of JAK/STAT signaling,GSK-3 inhibitor IX,NaN
gsk-j4,,,,,,,GSK-J4,KDM6A; KDM6B,inhibitor of lysine-specific demethylases,GSK-J4,KDM6A; KDM6B
gsk1059615,,,,,,,GSK1059615,MTOR; PIK3CA; PIK3CB; PIK3CD; PIK3CG,inhibitor of PI3K and mTOR kinase activity,GSK1059615,PIK3CA; MTOR; PIK3CB; PIK3CG; PIK3CD
gsk1070916,,,GSK1070916,GSK-1070916,AURKA; AURKC,Mitosis,,,,GSK1070916; GSK-1070916,AURKA; AURKC
gsk1904529a,,,GSK1904529A,"GSK-1904529A, GSK 1904529A",IGF1R; IR,IGFR signaling,,,,GSK 1904529A; GSK1904529A; GSK-1904529A,IR; IGF1R
gsk2636771,,,,,,,GSK2636771,PIK3CB,inhibitor of PI3K catalytic subunit beta,GSK2636771,PIK3CB
gsk269962a,,,GSK269962A,GSK 269962A,ROCK1; ROCK2,Cytoskeleton,,,,GSK269962A; GSK 269962A,ROCK2; ROCK1
gsk319347a,,,GSK319347A,"KIN001-135, IKK-3 inhibitor",IKK,Other,,,,GSK319347A; KIN001-135; IKK-3 inhibitor,IKK
gsk4112,,,,,,,GSK4112,NR1D1,antagonist of Rev-ErbAalpha,GSK4112,NR1D1
gsk429286a,,,GSK429286A,,ROCK1; ROCK2,Cytoskeleton,,,,GSK429286A,ROCK2; ROCK1
gsk461364,,,,,,,GSK461364,PLK1,inhibitor of polo-like kinase 1 (PLK1),GSK461364,PLK1
gsk650394,,,GSK650394,"GSK-650394, GSK 650394",SGK2; SGK3,Other,,,,GSK-650394; GSK 650394; GSK650394,SGK2; SGK3
gsk690693,,,GSK690693,"GSK 690693, GSK-690693",AKT1; AKT2; AKT3,PI3K/MTOR signaling,,,,GSK 690693; GSK690693; GSK-690693,AKT2; AKT1; AKT3
gw-2580,,,GW-2580,"GX2580, CFMS receptor tyrosine kinase inhibitor",CSF1R,RTK signaling,,,,GW-2580; GX2580; CFMS receptor tyrosine kinase inhibitor,CSF1R
gw-405833,,,,,,,GW-405833,CNR2,partial agonist of cannabinoid receptor 2,GW-405833,CNR2
gw-843682x,,,,,,,GW-843682X,PLK1; PLK3,inhibitor of PLK1 and PLK3,GW-843682X,PLK1; PLK3
gw441756,,,GW441756,GW 441756,NTRK1,RTK signaling,,,,GW 441756; GW441756,NTRK1
gw843682x,,,GW843682X,GW843682X (AN-13),PLK1,Cell cycle,,,,GW843682X; GW843682X (AN-13),PLK1
hbx-41108,,,,,,,HBX-41108,USP7,inhibitor of the deubiquitinase activity of USP7,HBX-41108,USP7
hc-067047,,,,,,,HC-067047,TRPV4,inhibitor of cation channel TRPV4,HC-067047,TRPV4
hg-5-113-01,,,HG-5-113-01,,LOK; LTK; TRCB; ABL(T315I),Other,,,,HG-5-113-01,LTK; LOK; TRCB; ABL(T315I)
hg-5-88-01,,,HG-5-88-01,,EGFR; ADCK4,"Other, kinases",,,,HG-5-88-01,ADCK4; EGFR
hg6-64-1,,,HG6-64-1,KIN001-206,BRAF,ERK MAPK signaling,,,,HG6-64-1; KIN001-206,BRAF
hli 373,,,,,,,HLI 373,MDM2,inhibitor of MDM2,HLI 373,MDM2
hyperforin,,,,,,,hyperforin,TRPC6,agonist of calcium-permeable ion channels,hyperforin,TRPC6
i-bet-762,,,I-BET-762,GSK525762A,BRD2; BRD3; BRD4,Chromatin other,GSK525762A,BRD2; BRD3; BRD4,inhibitor of bromodomain (BRD) and extra-C terminal domain (BET) proteins,I-BET-762; GSK525762A,BRD4; BRD2; BRD3
i-bet151,,,,,,,I-BET151,BRD2; BRD3; BRD4,inhibitor of bromodomain (BRD) and extra-C terminal domain (BET) proteins,I-BET151,BRD4; BRD2; BRD3
ibrutinib,,,,,,,ibrutinib,BTK,inhibitor of Bruton's tyrosine kinase,ibrutinib,BTK
ic-87114,,,,,,,IC-87114,PIK3CD,inhibitor of PI3K catalytic subunit delta,IC-87114,PIK3CD
icl1100013,,,ICL1100013,,N-myristoyltransferase 1/2,Other,,,,ICL1100013,N-myristoyltransferase 1/2
idelalisib,,,Idelalisib,"CAL-101, Zydelig",PI3Kdelta,PI3K/MTOR signaling,CAL-101,PIK3CD,inhibitor of PI3K catalytic subunit delta,Idelalisib; CAL-101; Zydelig,PI3Kdelta; PIK3CD
ifosfamide,,,,,,,ifosfamide,,DNA alkylator,ifosfamide,NaN
imatinib,,,Imatinib,"Gleevec, STI-571",ABL; KIT; PDGFR,RTK signaling,imatinib,ABL1; BCR; KIT,inhibitor of BCR-ABL1 and c-KIT,Imatinib; STI-571; imatinib; Gleevec,PDGFR; ABL1; KIT; BCR; ABL
importazole,,,,,,,importazole,KPNB1,inhibitor of importin,importazole,KPNB1
indisulam,,,,,,,indisulam,CA9,inhibitor of carbonic anhydrase isoform IX,indisulam,CA9
iox2,,,IOX2,"IOX-2, IOX 2, AK176060",EGLN1,Other,,,,IOX-2; IOX 2; IOX2; AK176060,EGLN1
ipa-3,,,IPA-3,IPA 3,PAK1,Cytoskeleton,,,,IPA 3; IPA-3,PAK1
ipr-456,,,,,,,IPR-456,PLAUR,inhibitor of the interaction of urokinase receptor with binding partners,IPR-456,PLAUR
irinotecan,Irinotecan,TOP1,,,,,,,,Irinotecan,TOP1
isoevodiamine,,,,,,,isoevodiamine,,natural product,isoevodiamine,NaN
isoliquiritigenin,,,,,,,isoliquiritigenin,,natural product,isoliquiritigenin,NaN
isonicotinohydroxamic acid,,,,,,,isonicotinohydroxamic acid,HDAC6,inhibitor of HDAC6,isonicotinohydroxamic acid,HDAC6
isox,,,,,,,ISOX,HDAC6,inhibitor of HDAC6,ISOX,HDAC6
isox:bortezomib (250:1 mol/mol),,,,,,,ISOX:bortezomib (250:1 mol/mol),HDAC6; PSMB1; PSMB2; PSMB5; PSMD1; PSMD2,inhibitor of HDAC6;inhibitor of 26S proteasome,ISOX:bortezomib (250:1 mol/mol),PSMB5; PSMD2; PSMB2; PSMD1; PSMB1; HDAC6
ispinesib mesylate,,,Ispinesib Mesylate,SB-715992,KSP,Mitosis,,,,SB-715992; Ispinesib Mesylate,KSP
istradefylline,,,,,,,istradefylline,ADORA2A,antagonist of the adenosine A2A receptor,istradefylline,ADORA2A
itraconazole,,,,,,,itraconazole,,anti-fungal agent; inhibitor of hedgehog signaling pathway,itraconazole,NaN
iu1,,,,,,,IU1,USP14,inhibitor of the deubiquitinase activity of USP14,IU1,USP14
jnk inhibitor viii,,,JNK Inhibitor VIII,,JNK,JNK and p38 signaling,,,,JNK Inhibitor VIII,JNK
jnk-9l,,,JNK-9L,"KIN001-204, JNK inhibitor 9l",JNK2; JNK3,JNK and p38 signaling,,,,JNK inhibitor 9l; KIN001-204; JNK-9L,JNK2; JNK3
jq-1:carboplatin (1:1 mol/mol),,,,,,,JQ-1:carboplatin (1:1 mol/mol),BRDT,inhibitor of bromodomain (BRD) and extra-C terminal domain (BET) proteins;inducer of DNA damage,JQ-1:carboplatin (1:1 mol/mol),BRDT
jq-1:mk-0752 (1:1 mol/mol),,,,,,,JQ-1:MK-0752 (1:1 mol/mol),BRDT; APH1A; NCSTN; PSEN1; PSENEN,inhibitor of bromodomain (BRD) and extra-C terminal domain (BET) proteins;inhibitor of gamma-secretase,JQ-1:MK-0752 (1:1 mol/mol),PSEN1; BRDT; NCSTN; PSENEN; APH1A
jq-1:navitoclax (2:1 mol/mol),,,,,,,JQ-1:navitoclax (2:1 mol/mol),BRDT; BCL2; BCL2L1; BCL2L2,"inhibitor of bromodomain (BRD) and extra-C terminal domain (BET) proteins;inhibitor of BCL2, BCL-xL, and BCL-W",JQ-1:navitoclax (2:1 mol/mol),BCL2; BCL2L2; BCL2L1; BRDT
jq-1:unc0638 (2:1 mol/mol),,,,,,,JQ-1:UNC0638 (2:1 mol/mol),BRDT; EHMT1; EHMT2,inhibitor of bromodomain (BRD) and extra-C terminal domain (BET) proteins;inhibitor of EHMT2 and GLP methyltransferase,JQ-1:UNC0638 (2:1 mol/mol),EHMT1; EHMT2; BRDT
jq-1:vorinostat (2:1 mol/mol),,,,,,,JQ-1:vorinostat (2:1 mol/mol),BRDT; HDAC1; HDAC2; HDAC3; HDAC6; HDAC8,"inhibitor of bromodomain (BRD) and extra-C terminal domain (BET) proteins;inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8",JQ-1:vorinostat (2:1 mol/mol),HDAC8; BRDT; HDAC1; HDAC3; HDAC2; HDAC6
jq1,,,JQ1,"JQ-1, (+)-JQ-1",BRD2; BRD3; BRD4; BRDT,Chromatin other,JQ-1,BRDT,inhibitor of bromodomain (BRD) and extra-C terminal domain (BET) proteins,JQ1; JQ-1; (+)-JQ-1,BRD4; BRD2; BRD3; BRDT
jq12,,,JQ12,,HDAC1; HDAC2,Chromatin histone acetylation,,,,JQ12,HDAC1; HDAC2
jw-480,,,,,,,JW-480,NCEH1,inhibitor of serine hydrolase enzyme NCEH,JW-480,NCEH1
jw-55,,,,,,,JW-55,TNKS,inhibitor of tankyrase,JW-55,TNKS
jw-7-24-1,,,JW-7-24-1,,LCK,"Other, kinases",,,,JW-7-24-1,LCK
jw-7-52-1,,,JW-7-52-1,,MTOR,PI3K/MTOR signaling,,,,JW-7-52-1,MTOR
jw-74,,,,,,,JW-74,,inhibitor of WNT signaling,JW-74,NaN
kh-cb19,,,,,,,KH-CB19,CLK1; CLK4,inhibitor of CDC2-like kinases 1 and 4,KH-CB19,CLK1; CLK4
khs101,,,,,,,KHS101,TACC3,"binder of TACC3, a component of the centrosome and mitotic spindle",KHS101,TACC3
ki8751,,,,,,,Ki8751,KDR; KIT; PDGFRA,"inhibitor of VEGFR2, c-KIT, and PDGFRA",Ki8751,PDGFRA; KDR; KIT
kin001-236,,,KIN001-236,,Angiopoietin-1 receptor,Other,,,,KIN001-236,Angiopoietin-1 receptor
kin001-244,,,KIN001-244,PDK1 inhibitor 7,PDK1 (PDPK1),"Other, kinases",,,,KIN001-244; PDK1 inhibitor 7,PDK1 (PDPK1)
kin001-260,,,KIN001-260,"Bayer IKKb inhibitor, ACHP",IKKB,Other,,,,ACHP; Bayer IKKb inhibitor; KIN001-260,IKKB
kin001-266,,,KIN001-266,,MAP3K8,"Other, kinases",,,,KIN001-266,MAP3K8
kin001-270,,,KIN001-270,"CDK9 inhibitor, CDK9-IN-1",CDK9,Cell cycle,,,,KIN001-270; CDK9-IN-1; CDK9 inhibitor,CDK9
ko-143,,,,,,,Ko-143,ABCG2,inhibitor of breast cancer resistance protein multidrug transporter (BCRP),Ko-143,ABCG2
kpt185,,,,,,,KPT185,XPO1,inhibitor of exportin 1,KPT185,XPO1
ku 0060648,,,,,,,KU 0060648,PRKDC,inhibitor of DNA-dependent protein kinase,KU 0060648,PRKDC
ku-0063794,,,,,,,KU-0063794,MTOR,inhibitor of mTOR,KU-0063794,MTOR
ku-55933,,,KU-55933,KU55933,ATM,Genome integrity,KU-55933,ATM,inhibitor of ataxia telangiectasia mutated (ATM),KU55933; KU-55933,ATM
ku-60019,,,,,,,KU-60019,ATM,inhibitor of ataxia telangiectasia mutated (ATM),KU-60019,ATM
kw-2449,,,,,,,KW-2449,AURKA; FLT3,inhibitor of FLT3 and AURKA,KW-2449,AURKA; FLT3
kx2-391,,,,,,,KX2-391,SRC,peptide mimetic; inhibitor of SRC activity in cells,KX2-391,SRC
l-685458,L-685458,GS,,,,,L-685458,APH1A; NCSTN; PSEN1; PSENEN,inhibitor of gamma-secretase,L-685458,PSEN1; PSENEN; GS; NCSTN; APH1A
lapatinib,Lapatinib,EGFR,Lapatinib,"Tykerb, Tyverb",ERBB2; EGFR,EGFR signaling,lapatinib,EGFR; ERBB2,inhibitor of EGFR and HER2,Tyverb; lapatinib; Lapatinib; Tykerb,EGFR; ERBB2
lbh-589,,,,,,,LBH-589,HDAC1; HDAC2; HDAC3; HDAC6; HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8",LBH-589,HDAC8; HDAC1; HDAC3; HDAC2; HDAC6
lbw242,LBW242,XIAP,,,,,,,,LBW242,XIAP
le-135,,,,,,,LE-135,RARB,antagonist of retinoic acid receptor beta,LE-135,RARB
lenalidomide,,,Lenalidomide,"CDC-501, CC-5013, Revlimid",CRBN,Protein stability and degradation,,,,Lenalidomide; CDC-501; Revlimid; CC-5013,CRBN
lenvatinib,,,,,,,lenvatinib,FLT1; FLT3; KDR; KIT; PDGFRA; PDGFRB,"inhibitor of VEGFRs, c-KIT, and PDGFR alpha and beta",lenvatinib,KDR; PDGFRB; PDGFRA; KIT; FLT1; FLT3
leptomycin b,,,,,,,leptomycin B,XPO1,inhibitor of exportin 1,leptomycin B,XPO1
lestaurtinib,,,Lestaurtinib,"CEP-701, SP-924, SPM-924, A-154475, KT-555",FLT3; JAK2; NTRK1; NTRK2; NTRK3,"Other, kinases",,,,A-154475; SPM-924; CEP-701; Lestaurtinib; KT-555; SP-924,NTRK3; NTRK2; JAK2; NTRK1; FLT3
lfm-a13,,,LFM-A13,DDE-28,BTK,"Other, kinases",,,,DDE-28; LFM-A13,BTK
linifanib,,,Linifanib,"ABT-869, ABT 869",VEGFR1; VEGFR2; VEGFR3; CSF1R; FLT3; KIT,RTK signaling,linifanib,FLT1; FLT3; KDR,inhibitor of VEGFRs,ABT-869; ABT 869; Linifanib; linifanib,VEGFR3; KDR; VEGFR2; CSF1R; KIT; VEGFR1; FLT1; FLT3
linsitinib,,,Linsitinib,"OSI-906, ASP-7487",IGF1R,IGFR signaling,linsitinib,IGF1R; INSR,inhibitor of insulin-like growth factor 1 receptor and insulin receptor,OSI-906; linsitinib; Linsitinib; ASP-7487,INSR; IGF1R
lomeguatrib,,,,,,,lomeguatrib,MGMT,inhibitor of methylguanine-DNA methyltransferase,lomeguatrib,MGMT
lovastatin,,,,,,,lovastatin,HMGCR,inhibitor of HMG-CoA reductase,lovastatin,HMGCR
lrrk2-in-1,,,,,,,LRRK2-IN-1,DCLK1; LRRK2,inhibitor of leucine-rich repeat kinase 2; inhibitor of doublecortin-like kinase,LRRK2-IN-1,LRRK2; DCLK1
luminespib,,,Luminespib,"AUY922, VER-52296,NVP-AUY922,  AUY",HSP90,Protein stability and degradation,,,,"Luminespib;  AUY; AUY922; VER-52296,NVP-AUY922",HSP90
ly-2157299,,,,,,,LY-2157299,TGFBR1,inhibitor of the transforming growth factor beta type 1 receptor,LY-2157299,TGFBR1
ly-2183240,,,,,,,LY-2183240,FAAH,inhibitor of fatty acid amide hydrolase; inhibitor of anandamide uptake,LY-2183240,FAAH
manumycin a,,,,,,,manumycin A,FNTA; FNTB,inhibitor of RAS farnesyltransferase,manumycin A,FNTB; FNTA
marinopyrrole a,,,,,,,marinopyrrole A,MCL1,natural product; putative inhibitor of MCL1,marinopyrrole A,MCL1
masitinib,,,Masitinib,"AB1010, Masivet",KIT; PDGFRA; PDGFRB,"Other, kinases",masitinib,KIT; PDGFRA; PDGFRB,"inhibitor of c-KIT, PDGFRA, and PDGFRB",Masivet; Masitinib; masitinib; AB1010,PDGFRB; PDGFRA; KIT
mdivi-1,,,,,,,Mdivi-1,DNM1,inhibitor of dynamin 1; inhibitor of mitrochondrial division inhibitor,Mdivi-1,DNM1
merck60,,,,,,,Merck60,HDAC1; HDAC2,inhibitor of HDAC1 and HDAC2,Merck60,HDAC1; HDAC2
methotrexate,,,Methotrexate,"Abitrexate, Amethopterin, Rheumatrex, Trexall, Folex",Antimetabolite,DNA replication,methotrexate,DHFR,inhibitor of dihydrofolate reductase,Methotrexate; Folex; Rheumatrex; Trexall; methotrexate; Abitrexate; Amethopterin,DHFR; Antimetabolite
methylstat,,,,,,,methylstat,KDM3A; KDM4A; KDM4B; KDM4C; KDM4D,inhibitor of lysine specific demethylases,methylstat,KDM4D; KDM4B; KDM4A; KDM3A; KDM4C
mg-132,,,MG-132,"LLL cpd, MG 132, MG132",Proteasome; CAPN1,Protein stability and degradation,MG-132,PSMB1; PSMB2; PSMB5; PSMD1; PSMD2,inhibitor of the proteosome,MG-132; MG132; MG 132; LLL cpd,CAPN1; PSMB5; PSMD2; PSMB2; PSMD1; PSMB1; Proteasome
mgcd-265,,,,,,,MGCD-265,FLT1; FLT3; KDR; MET,inhibitor of c-MET and VEGFRs,MGCD-265,FLT1; KDR; MET; FLT3
mi-1,,,,,,,MI-1,MEN1,binder of menin; inhibitor of menin-MLL fusion protein,MI-1,MEN1
mi-2,,,,,,,MI-2,MEN1,binder of menin; inhibitor of menin-MLL fusion protein,MI-2,MEN1
midostaurin,,,Midostaurin,"PKC412, benzoylstaurosporine, CGP-41251",PKC; PPK; FLT1; c-FGR; others,Other,,,,CGP-41251; PKC412; Midostaurin; benzoylstaurosporine,PPK; PKC; others; c-FGR; FLT1
mitomycin,,,,,,,mitomycin,,DNA crosslinker,mitomycin,NaN
mitomycin-c,,,Mitomycin-C,"Mytozytrex, NSC-26980, MMC, Mitosol, Mitozytrex",DNA crosslinker,DNA replication,,,,MMC; Mytozytrex; Mitomycin-C; Mitosol; NSC-26980; Mitozytrex,DNA crosslinker
mk-0752,,,,,,,MK-0752,APH1A; NCSTN; PSEN1; PSENEN,inhibitor of gamma-secretase,MK-0752,PSEN1; APH1A; NCSTN; PSENEN
mk-1775,,,,,,,MK-1775,WEE1,inhibitor of WEE1,MK-1775,WEE1
mk-2206,,,MK-2206,"MK 2206, MK2206",AKT1; AKT2,PI3K/MTOR signaling,MK-2206,AKT1,inhibitor of AKT1,MK 2206; MK-2206; MK2206,AKT2; AKT1
ml006,,,,,,,ML006,S1PR3,agonist of sphingosine 1-phosphate receptor 3,ML006,S1PR3
ml029,,,,,,,ML029,,inhibitor of antigen receptor-mediated NFkappaB activity,ML029,NaN
ml031,,,,,,,ML031,S1PR2,inhibitor of sphingosine 1-phosphate receptor 2,ML031,S1PR2
ml050,,,,,,,ML050,GPER1,antagonist of GPR30,ML050,GPER1
ml083,,,,,,,ML083,PKM,activator of muscle pyruvate kinase,ML083,PKM
ml162,,,,,,,ML162,,selectively kills engineered cells expressing mutant HRAS,ML162,NaN
ml203,,,,,,,ML203,PKM,activator of muscle pyruvate kinase (PKM2),ML203,PKM
ml210,,,,,,,ML210,,selectively kills engineered cells expressing mutant HRAS,ML210,NaN
ml239,,,,,,,ML239,,ML239; inhibitor of breast cancer stem cell proliferation,ML239,NaN
ml258,,,,,,,ML258,BCL2L10,inhibitor of BIM-BCL-B interaction,ML258,BCL2L10
ml311,,,,,,,ML311,MCL1,inhibitor of MCL1,ML311,MCL1
ml312,,,,,,,ML312,SCARB1,"inhibitor of scavenger receptor class B, member 1 (SCARB1)-mediated lipid uptake",ML312,SCARB1
ml320,,,,,,,ML320,GSK3B,inhibitor of GSK3 beta,ML320,GSK3B
ml334 diastereomer,,,,,,,ML334 diastereomer,KEAP1; NFE2L2,inhibitor of KEAP1-NFE2L2 protein-protein interaction,ML334 diastereomer,KEAP1; NFE2L2
mln2238,,,,,,,MLN2238,PSMB5,inhibitor of 20S proteasome at the chymotrypsin-like proteolytic (beta-5) site,MLN2238,PSMB5
mln2480,,,,,,,MLN2480,ARAF; BRAF; RAF1,inhibitor of RAF kinases,MLN2480,BRAF; ARAF; RAF1
momelotinib,,,,,,,momelotinib,JAK1; JAK2,inhibitor of Janus kinases 1 and 2,momelotinib,JAK2; JAK1
motesanib,,,Motesanib,"AMG-706, AMG 706, AMG706",VEGFR; RET; KIT; PDGFR,RTK signaling,,,,AMG-706; AMG 706; AMG706; Motesanib,PDGFR; VEGFR; RET; KIT
mps-1-in-1,,,MPS-1-IN-1,,MPS1,Mitosis,,,,MPS-1-IN-1,MPS1
mst-312,,,,,,,MST-312,TERT,inhibitor of telomerase reverse transcriptase,MST-312,TERT
myricetin,,,,,,,myricetin,,flavonoid antioxidant,myricetin,NaN
myriocin,,,,,,,myriocin,SPTLC1; SPTLC2; SPTLC3,inhibitor of serine palmitoyltransferase,myriocin,SPTLC2; SPTLC1; SPTLC3
n9-isopropylolomoucine,,,,,,,N9-isopropylolomoucine,CCNB1; CDK1; CDK5; CDK5R1,inhibitor of CDK1/cyclin B and CDK5/p35 complexes,N9-isopropylolomoucine,CDK1; CCNB1; CDK5R1; CDK5
nakiterpiosin,,,,,,,nakiterpiosin,,natural product; inhibitor of microtubule assembly,nakiterpiosin,NaN
narciclasine,,,,,,,narciclasine,RHOA,activates cellular activity of RhoA; modulator of Rho/Rho kinase/LIM kinase/cofilin signaling,narciclasine,RHOA
navitoclax,,,Navitoclax,"ABT-263, ABT263, ABT 263",BCL2; BCL-XL; BCL-W,Apoptosis regulation,navitoclax,BCL2; BCL2L1; BCL2L2,"inhibitor of BCL2, BCL-xL, and BCL-W",ABT263; ABT-263; ABT 263; navitoclax; Navitoclax,BCL-W; BCL2; BCL2L2; BCL2L1; BCL-XL
navitoclax:birinapant (1:1 mol/mol),,,,,,,navitoclax:birinapant (1:1 mol/mol),BCL2; BCL2L1; BCL2L2; DIABLO; XIAP,"inhibitor of BCL2, BCL-xL, and BCL-W;SMAC mimetic; inhibitor of inhibitor of apoptosis proteins (IAPs)",navitoclax:birinapant (1:1 mol/mol),DIABLO; BCL2; BCL2L2; BCL2L1; XIAP
navitoclax:gemcitabine (1:1 mol/mol),,,,,,,navitoclax:gemcitabine (1:1 mol/mol),BCL2; BCL2L1; BCL2L2; CMPK1; RRM1; TYMS,"inhibitor of BCL2, BCL-xL, and BCL-W;inhibitor of DNA replication; inhibitor of ribonucleotide reductase, thymidylate synthetase, and cytidine monophosphate (UMP-CMP) kinase ",navitoclax:gemcitabine (1:1 mol/mol),CMPK1; RRM1; TYMS; BCL2; BCL2L2; BCL2L1
navitoclax:mst-312 (1:1 mol/mol),,,,,,,navitoclax:MST-312 (1:1 mol/mol),BCL2; BCL2L1; BCL2L2; TERT,"inhibitor of BCL2, BCL-xL, and BCL-W;inhibitor of telomerase reverse transcriptase",navitoclax:MST-312 (1:1 mol/mol),BCL2; BCL2L2; BCL2L1; TERT
navitoclax:piperlongumine (1:1 mol/mol),,,,,,,navitoclax:piperlongumine (1:1 mol/mol),BCL2; BCL2L1; BCL2L2,"inhibitor of BCL2, BCL-xL, and BCL-W;natural product; modulator of ROS levels",navitoclax:piperlongumine (1:1 mol/mol),BCL2; BCL2L2; BCL2L1
navitoclax:pluripotin (1:1 mol/mol),,,,,,,navitoclax:pluripotin (1:1 mol/mol),BCL2; BCL2L1; BCL2L2; MAPK1; RASAL1,"inhibitor of BCL2, BCL-xL, and BCL-W;promoter of embryonic stem cell self-renewal; inhibitor of Ras-GAP and ERK",navitoclax:pluripotin (1:1 mol/mol),BCL2; BCL2L2; BCL2L1; MAPK1; RASAL1
navitoclax:plx-4032 (1:1 mol/mol),,,,,,,navitoclax:PLX-4032 (1:1 mol/mol),BCL2; BCL2L1; BCL2L2; BRAF,"inhibitor of BCL2, BCL-xL, and BCL-W;inhibitor of BRAF",navitoclax:PLX-4032 (1:1 mol/mol),BCL2; BCL2L2; BCL2L1; BRAF
navitoclax:sorafenib (1:1 mol/mol),,,,,,,navitoclax:sorafenib (1:1 mol/mol),BCL2; BCL2L1; BCL2L2; BRAF; FLT3; KDR; RAF1,"inhibitor of BCL2, BCL-xL, and BCL-W;inhibitor of BRAF, CRAF, and VEGFR2",navitoclax:sorafenib (1:1 mol/mol),KDR; BCL2; BCL2L2; BRAF; BCL2L1; RAF1; FLT3
necrostatin-1,,,,,,,necrostatin-1,RIPK1,inhibitor of receptor-interacting protein kinase 1; inhibitor of the necroptosis cell death pathway,necrostatin-1,RIPK1
necrostatin-7,,,,,,,necrostatin-7,,inhibitor of necroptosis,necrostatin-7,NaN
necrosulfonamide,,,,,,,necrosulfonamide,,inhibitor of downstream signaling of RIP3 associated with MLKL,necrosulfonamide,NaN
nelarabine,,,,,,,nelarabine,POLA1,deoxyguanosine analog; inhibitor of DNA synthesis,nelarabine,POLA1
neopeltolide,,,,,,,neopeltolide,,inhibitor of cellular respiration,neopeltolide,NaN
neratinib,,,,,,,neratinib,EGFR; ERBB2,inhibitor of EGFR and HER2,neratinib,EGFR; ERBB2
neuronal differentiation inducer iii,,,,,,,neuronal differentiation inducer III,,induction of rat HCN cell differentiation as judged by induction of neuronal reporter neuroD activity,neuronal differentiation inducer III,NaN
ng-25,,,NG-25,NG25,TAK1; MAP4K2,"Other, kinases",,,,NG25; NG-25,MAP4K2; TAK1
niclosamide,,,,,,,niclosamide,STAT3,inhibitor of STAT3 signaling,niclosamide,STAT3
nilotinib,Nilotinib,ABL,Nilotinib,"Tasigna, AMN 107",ABL,ABL signaling,nilotinib,ABL1; BCR; KIT,"inhibitor of ABL1, BCR, and c-KIT",AMN 107; Tasigna; Nilotinib; nilotinib,ABL; ABL1; KIT; BCR
nintedanib,,,,,,,nintedanib,FGFR1; FGFR2; FGFR3; FLT1; FLT3; KDR; PDGFRA; PDGFRB,"inhibitor of c-KIT, VEGFRs, PDGFRs, and FGFRs",nintedanib,KDR; PDGFRB; PDGFRA; FGFR2; FGFR1; FGFR3; FLT1; FLT3
npc-26,,,,,,,NPC-26,,"induces cell death through a non-apoptotic, mitochondrial-dependent mechanism",NPC-26,NaN
npk76-ii-72-1,,,NPK76-II-72-1,,PLK3,Cell cycle,,,,NPK76-II-72-1,PLK3
nsc 74859,,,,,,,NSC 74859,STAT3,inhibitor of STAT3,NSC 74859,STAT3
nsc-207895,,,NSC-207895,"XI-006, NSC207895",MDM4,p53 pathway,,,,NSC207895; NSC-207895; XI-006,MDM4
nsc-87877,,,NSC-87877,NSC 87877,SHP-1 (PTPN6); SHP-2 (PTPN11),Other,,,,NSC-87877; NSC 87877,SHP-1 (PTPN6); SHP-2 (PTPN11)
nsc19630,,,,,,,NSC19630,WRN,inhibitor of Werner syndrome helicase activity,NSC19630,WRN
nsc23766,,,,,,,NSC23766,RAC1; TIAM1; TRIO,inhibitor of RAC1-GEF interaction; prevents Rac1 activation by Rac-specific guanine nucleotide exchange factors (GEFs) TrioN and Tiam1,NSC23766,RAC1; TIAM1; TRIO
nsc30930,,,,,,,NSC30930,SRD5A2,inhibitor of steroid 5-alpha reductase,NSC30930,SRD5A2
nsc48300,,,,,,,NSC48300,TASP1,inhibitor of threonine endopeptidase taspase 1,NSC48300,TASP1
nsc632839,,,,,,,NSC632839,USP13; USP5,inhibitor of ubiquitin isopeptidase,NSC632839,USP13; USP5
nsc95397,,,,,,,NSC95397,CDC25A; CDC25B; CDC25C,inhibitor of cell division cycle 25 phosphatase (CDC25),NSC95397,CDC25C; CDC25A; CDC25B
nu7441,,,NU7441,"KU-57788, NU-7432, NU-7741",DNAPK,Genome integrity,,,,KU-57788; NU7441; NU-7432; NU-7741,DNAPK
nutlin-3,Nutlin-3,MDM2,,,,,nutlin-3,MDM2,inhibitor of p53-MDM2 interaction,Nutlin-3; nutlin-3,MDM2
nutlin-3a (-),,,Nutlin-3a (-),,MDM2,p53 pathway,,,,Nutlin-3a (-),MDM2
nvp-231,,,,,,,NVP-231,CERK,inhibitor of ceramide kinase,NVP-231,CERK
nvp-adw742,,,,,,,NVP-ADW742,IGF1R,inhibitor of insulin-like growth factor 1 receptor,NVP-ADW742,IGF1R
nvp-bhg712,,,NVP-BHG712,BHG712,EPHB4,Other,,,,BHG712; NVP-BHG712,EPHB4
nvp-bsk805,,,,,,,NVP-BSK805,JAK2,inhibitor of Janus kinase 2,NVP-BSK805,JAK2
o-6-benzylguanine,,,,,,,O-6-benzylguanine,MGMT,inhibitor of O(6)-alkylguanine DNA alkyltransferases,O-6-benzylguanine,MGMT
obatoclax,,,Obatoclax Mesylate,"GX15-070MS, Obatoclax, GX15-070",BCL2; BCL-XL; BCL-W; MCL1,Apoptosis regulation,obatoclax,BCL2; BCL2L1; MCL1,"inhibitor of MCL1, BCL2, and BCL-xL",GX15-070; obatoclax; Obatoclax Mesylate; Obatoclax; GX15-070MS,MCL1; BCL-W; BCL2; BCL2L1; BCL-XL
olaparib,,,Olaparib,"AZD2281, KU0059436,  Lynparza",PARP1; PARP2,Genome integrity,olaparib,PARP1; PARP2,inhibitor of poly (ADP-ribose) polymerase 1 and 2, Lynparza; AZD2281; Olaparib; olaparib; KU0059436,PARP1; PARP2
oligomycin a,,,,,,,oligomycin A,ATP5L2,inhibitor of mitochondrial ATP synthase,oligomycin A,ATP5L2
omacetaxine mepesuccinate,,,,,,,omacetaxine mepesuccinate,,inhibitor of protein translation by preventing protein elongation,omacetaxine mepesuccinate,NaN
omipalisib,,,Omipalisib,"GSK2126458, GSK-2126458, EX-8678, GSK458",PI3K (class 1); MTORC1; MTORC2,PI3K/MTOR signaling,,,,Omipalisib; GSK2126458; GSK458; EX-8678; GSK-2126458,PI3K (class 1); MTORC2; MTORC1
osi-027,,,OSI-027,A-1065-5,MTORC1; MTORC2,PI3K/MTOR signaling,OSI-027,MTOR,inhibitor of mTORC1 and mTORC2,A-1065-5; OSI-027,MTORC2; MTORC1; MTOR
osi-930,,,OSI-930,OSI 930 OSI930,KIT,RTK signaling,OSI-930,KDR; KIT,inhibitor of c-KIT and VEGFR2,OSI 930 OSI930; OSI-930,KDR; KIT
osu-03012,,,OSU-03012,"AR-12, OSU 03012, OSU03012, PDK1 inhibitor AR-12",PDK1 (PDPK1),"Other, kinases",,,,OSU 03012; PDK1 inhibitor AR-12; AR-12; OSU03012; OSU-03012,PDK1 (PDPK1)
ouabain,,,,,,,ouabain,ATP1A1; ATP1A2; ATP1A3; ATP1A4; ATP1B1; ATP1B2; ATP1B3; ATP1B4,cardiac glycoside; inhibitor of the Na+/K+-ATPase,ouabain,ATP1B3; ATP1A2; ATP1A1; ATP1A4; ATP1B2; ATP1B1; ATP1B4; ATP1A3
oxaliplatin,,,,,,,oxaliplatin,,DNA alkylator; organoplatinum reagent,oxaliplatin,NaN
pac-1,,,PAC-1,GTPL5238,Procaspase-3; Procaspase-7,Apoptosis regulation,PAC-1,CASP3,activator of procaspase-3,PAC-1; GTPL5238,Procaspase-3; CASP3; Procaspase-7
paclitaxel,Paclitaxel,TUBB1,Paclitaxel,"BMS-181339-01, Taxol, Onxol, Paxene, Praxel, Abraxane",Microtubule stabiliser,Mitosis,paclitaxel,,inhibitor of microtubule assembly,paclitaxel; Paxene; Abraxane; Paclitaxel; Onxol; BMS-181339-01; Taxol; Praxel,Microtubule stabiliser; TUBB1
palbociclib,PD-0332991,CDK4,Palbociclib,"PD0332991, PD-0332991, PF-00080665-73",CDK4; CDK6,Cell cycle,,,,PF-00080665-73; Palbociclib; PD-0332991; PD0332991,CDK4; CDK6
palmostatin b,,,,,,,palmostatin B,LYPLA1,inhibitor of acyl-protein thioesterase 1,palmostatin B,LYPLA1
pandacostat,,,,,,,pandacostat,HDAC1; HDAC2; HDAC3; HDAC6; HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8",pandacostat,HDAC8; HDAC1; HDAC3; HDAC2; HDAC6
panobinostat,Panobinostat,HDAC,,,,,,,,Panobinostat,HDAC
parbendazole,,,,,,,parbendazole,,inhibitor of microtubule assembly,parbendazole,NaN
parthenolide,,,Parthenolide,,HDAC1 ,Chromatin histone acetylation,parthenolide,,natural product; modulator of ROS; modulator of NF-kappa-B signaling,Parthenolide; parthenolide,HDAC1 
pazopanib,,,Pazopanib,Votrient,CSF1R; KIT;  PDGFRA; PDGFRB,RTK signaling,pazopanib,FLT1; FLT3; KDR; KIT; PDGFRB,"inhibitor of VEGFRs, c-KIT, and PDGFRB",Votrient; pazopanib; Pazopanib,KDR; PDGFRB;  PDGFRA; KIT; CSF1R; FLT1; FLT3
pd 153035,,,,,,,PD 153035,EGFR,inhibitor of EGFR,PD 153035,EGFR
pd0325901,PD-0325901,MEK,PD0325901,"PD-0325901, PD 0325901",MEK1; MEK2,ERK MAPK signaling,,,,PD-0325901; PD0325901; PD 0325901,MEK1; MEK2; MEK
pd173074,,,PD173074,"PD-173074, PD 173074",FGFR1; FGFR3,RTK signaling,,,,PD173074; PD 173074; PD-173074,FGFR1; FGFR3
pd318088,,,,,,,PD318088,MAP2K1; MAP2K2,inhibitor of MEK1 and MEK2,PD318088,MAP2K1; MAP2K2
pdmp,,,,,,,PDMP,UGCG,inhibitor of ceramide glucosyltransferase,PDMP,UGCG
pelitinib,,,Pelitinib,"EKB-569, EKB 569",EGFR,EGFR signaling,,,,EKB-569; EKB 569; Pelitinib,EGFR
pevonedistat,,,Pevonedistat,"MLN4924, MLN 4924, MLN-4924",NAE,Other,pevonedistat,NAE1,inhibitor of Nedd-8 activating enzyme,MLN-4924; MLN4924; pevonedistat; MLN 4924; Pevonedistat,NAE1; NAE
pf-184,,,,,,,PF-184,IKBKB,inhibitor of IKK-2,PF-184,IKBKB
pf-3758309,,,,,,,PF-3758309,PAK4,inhibitor of serine/threonine p21-activating kinase 4,PF-3758309,PAK4
pf-4708671,,,PF-4708671,"PF 4708671, PF4708671",S6K1,PI3K/MTOR signaling,,,,PF 4708671; PF-4708671; PF4708671,S6K1
pf-4800567 hydrochloride,,,,,,,PF-4800567 hydrochloride,CSNK1D; CSNK1E,inhibitor of casein kinase isoforms delta and epsilon,PF-4800567 hydrochloride,CSNK1E; CSNK1D
pf-543,,,,,,,PF-543,SPHK1,inhibitor of sphingosine kinase-1,PF-543,SPHK1
pf-562271,,,PF-562271,PF-00562271,FAK; FAK2,Cytoskeleton,,,,PF-00562271; PF-562271,FAK2; FAK
pf-573228,,,,,,,PF-573228,PTK2,inhibitor of focal adhesion kinase,PF-573228,PTK2
pf-750,,,,,,,PF-750,FAAH,inhibitor of fatty acid amide hydrolase,PF-750,FAAH
pfi-1,,,PFI-1,,BRD4,Chromatin other,,,,PFI-1,BRD4
pfi-3,,,PFI-3,BDF00016096,SMARCA2; SMARCA4; PB1,Other,,,,PFI-3; BDF00016096,SMARCA4; PB1; SMARCA2
pha-665752,PHA-665752,c-MET,PHA-665752,"PHA665752, PHA 665752",MET,RTK signaling,,,,PHA665752; PHA 665752; PHA-665752,c-MET; MET
pha-793887,,,PHA-793887,"PHA793887, PHA 793887",CDK2; CDK7; CDK5,Cell cycle,PHA-793887,CDK1; CDK2; CDK4; CDK5; CDK7; CDK9,inhibitor of cyclin-dependent kinases,PHA-793887; PHA 793887; PHA793887,CDK4; CDK5; CDK1; CDK2; CDK9; CDK7
phenformin,,,Phenformin,DBI,Biguanide agent,Other,,,,DBI; Phenformin,Biguanide agent
phloretin,,,,,,,phloretin,SLC5A1,natural product; inhibitor of glucose uptake,phloretin,SLC5A1
pi-103,,,PI-103,"PI-103, PI103, PI 103",PI3Kalpha; DAPK3; CLK4; PIM3; HIPK2,PI3K/MTOR signaling,PI-103,MTOR; PIK3CA; PIK3CB; PIK3CD; PIK3CG; PRKDC,"inhibitor of DNA-PK, PI3K p110 delta, mTORC1, and catalytic subunits of PI3K",PI-103; PI 103; PI103,DAPK3; PRKDC; PIK3CA; CLK4; MTOR; HIPK2; PI3Kalpha; PIK3CB; PIK3CG; PIM3; PIK3CD
pictilisib,,,Pictilisib,"GDC-0941, GDC0941, RG-7621",PI3K (class 1),PI3K/MTOR signaling,GDC-0941,PIK3CA; PIK3CB; PIK3CD; PIK3CG,inhibitor of PI3K kinase activity,GDC-0941; Pictilisib; GDC0941; RG-7621,PI3K (class 1); PIK3CA; PIK3CB; PIK3CG; PIK3CD
pifithrin-alpha,,,,,,,pifithrin-alpha,,inhibitor of p53-dependent signaling,pifithrin-alpha,NaN
pifithrin-mu,,,,,,,pifithrin-mu,HSPA1A; HSPA1B; HSPA1L; TP53,inhibitor of p53 binding to mitochondria; inhibitor of HSP70,pifithrin-mu,HSPA1A; TP53; HSPA1B; HSPA1L
pik-93,,,PIK-93,"PIK 93, PIK93",PI3Kgamma,PI3K/MTOR signaling,PIK-93,PIK3CG,inhibitor of PI3K catalytic subunit gamma,PIK93; PIK-93; PIK 93,PI3Kgamma; PIK3CG
piperlongumine,,,Piperlongumine,Piplartine,Induces reactive oxygen species,Other,piperlongumine,,natural product; modulator of ROS levels,piperlongumine; Piplartine; Piperlongumine,Induces reactive oxygen species
piperlongumine:mst-312 (1:1 mol/mol),,,,,,,piperlongumine:MST-312 (1:1 mol/mol),TERT,natural product; modulator of ROS levels;inhibitor of telomerase reverse transcriptase,piperlongumine:MST-312 (1:1 mol/mol),TERT
pitstop2,,,,,,,pitstop2,CLTA; CLTB; CLTC; CLTCL1,inhibitor of clathrin and clathrin-independent endocytosis,pitstop2,CLTC; CLTB; CLTA; CLTCL1
pl-di,,,,,,,PL-DI,,dimer of piperlongumine; inducer of ROS,PL-DI,NaN
platin,,,,,,,Platin,,DNA alkylator; organoplatinum reagent,Platin,NaN
pluripotin,,,,,,,pluripotin,MAPK1; RASAL1,promoter of embryonic stem cell self-renewal; inhibitor of Ras-GAP and ERK,pluripotin,MAPK1; RASAL1
plx-4032,,,,,,,PLX-4032,BRAF,inhibitor of BRAF,PLX-4032,BRAF
plx4720,PLX4720,RAF,PLX-4720,"PLX4720, PLX 4720",BRAF,ERK MAPK signaling,PLX-4720,BRAF,inhibitor of BRAF,PLX-4720; PLX4720; PLX 4720,BRAF; RAF
ponatinib,,,Ponatinib,"AP24534, AP-24534, KIN001-192, Iclusig",ABL; PDGFRA; VEGFR2; FGFR1; SRC; TIE2; FLT3,RTK signaling,,,,Ponatinib; AP-24534; Iclusig; KIN001-192; AP24534,PDGFRA; VEGFR2; FGFR1; SRC; ABL; TIE2; FLT3
prima-1,,,,,,,PRIMA-1,TP53,re-activator of the pro-apoptotic activity of mutant p53,PRIMA-1,TP53
prima-1-met,,,,,,,PRIMA-1-Met,TP53,re-activator of the pro-apoptotic activity of mutant p53,PRIMA-1-Met,TP53
prl-3 inhibitor i,,,,,,,PRL-3 inhibitor I,PTP4A3,inhibitor of phosphatase of regenerating liver-3 (PRL3),PRL-3 inhibitor I,PTP4A3
procarbazine,,,,,,,procarbazine,,inducer of DNA damage,procarbazine,NaN
prochlorperazine,,,,,,,prochlorperazine,DRD2,inhibitor of dopamine receptor D2,prochlorperazine,DRD2
purmorphamine,,,,,,,purmorphamine,SMO,activator of smoothened receptor,purmorphamine,SMO
px-12,,,,,,,PX-12,TXN,inhibitor of thioredoxin-1,PX-12,TXN
pyr-41,,,,,,,PYR-41,UBA1,inhibitor of ubiquitin-activating enzyme in cells,PYR-41,UBA1
pyrazolanthrone,,,,,,,pyrazolanthrone,MAPK10; MAPK8; MAPK9,inhibitor of Jun N-terminal kinase (JNK) 1/2/3,pyrazolanthrone,MAPK10; MAPK8; MAPK9
pyrimethamine,,,Pyrimethamine,"Daraprim, Chloridine",Dihydrofolate reductase (DHFR),Other,,,,Daraprim; Pyrimethamine; Chloridine,Dihydrofolate reductase (DHFR)
ql-viii-58,,,QL-VIII-58,,MTOR; ATR,Other,,,,QL-VIII-58,ATR; MTOR
ql-x-138,,,QL-X-138,,BTK,"Other, kinases",,,,QL-X-138,BTK
ql-xi-92,,,QL-XI-92,,DDR1,Other,,,,QL-XI-92,DDR1
ql-xii-47,,,QL-XII-47,,BTK; BMX,"Other, kinases",,,,QL-XII-47,BTK; BMX
ql-xii-61,,,QL-XII-61,,BMX; BTK,"Other, kinases",,,,QL-XII-61,BTK; BMX
qs-11,,,,,,,QS-11,ARFGAP1,inhibitor of GTPase activating protein of ARF 1 (ARFGAP1),QS-11,ARFGAP1
qs11,,,QS11,944328-88-5,ARFGAP1,Other,,,,944328-88-5; QS11,ARFGAP1
quizartinib,,,Quizartinib,"AC220, AC 220, AC-220, Asp-2689",FLT3,RTK signaling,quizartinib,FLT3,inhibtor of VEGFR3,AC220; AC 220; Asp-2689; Quizartinib; AC-220; quizartinib,FLT3
qw-bi-011,,,,,,,QW-BI-011,EHMT2,inhibitor of G9a histone methyltransferase,QW-BI-011,EHMT2
r428,,,,,,,R428,AXL,inhibitor of the tyrosine-protein kinase receptor UFO,R428,AXL
raf265,RAF265,RAF,,,,,RAF265,BRAF; KDR,ihibitor of VEGFR2 and BRAF,RAF265,BRAF; KDR; RAF
refametinib,,,Refametinib,"RDEA119, BAY-86-9766, BAY 869766",MEK1; MEK2,ERK MAPK signaling,,,,Refametinib; RDEA119; BAY-86-9766; BAY 869766,MEK1; MEK2
regorafenib,,,,,,,regorafenib,BRAF; KDR; KIT; RET,"inhibitor of BRAF, RET, KIT, and VEGFR2",regorafenib,BRAF; RET; KDR; KIT
repligen 136,,,,,,,Repligen 136,HDAC3,inhibitor of HDAC3,Repligen 136,HDAC3
rg-108,,,,,,,RG-108,DNMT1,inhibitor of DNA methyltransferase,RG-108,DNMT1
rigosertib,,,,,,,rigosertib,PIK3CA; PIK3CB; PLK1,inhibitor of polo-like kinase 1; inhibitor of PI3K catalytic subunits alpha and beta,rigosertib,PIK3CB; PIK3CA; PLK1
rita,,,,,,,RITA,MDM2; TP53,inhibitor of p53-MDM2 interaction,RITA,TP53; MDM2
ro-3306,,,RO-3306,,CDK1,Cell cycle,,,,RO-3306,CDK1
ro4929097,,,,,,,RO4929097,APH1A; NCSTN; PSEN1; PSENEN,inhibitor of gamma-secretase,RO4929097,PSEN1; APH1A; NCSTN; PSENEN
rtrail,,,rTRAIL,,TRAIL receptor agonist,Apoptosis regulation,,,,rTRAIL,TRAIL receptor agonist
rucaparib,,,Rucaparib,"PF-01367338, AG-014699, AG-14447, AG-14699",PARP1; PARP2,Genome integrity,,,,AG-14699; PF-01367338; AG-14447; Rucaparib; AG-014699,PARP1; PARP2
ruxolitinib,,,Ruxolitinib,"INCB-18424, Ruxolitinib Phosphate, Jakafi",JAK1; JAK2,"Other, kinases",ruxolitinib,JAK1; JAK2,inhibitor of Janus kinases 1 and 2,Jakafi; Ruxolitinib; INCB-18424; Ruxolitinib Phosphate; ruxolitinib,JAK2; JAK1
s-trityl-l-cysteine,,,S-Trityl-L-cysteine,"NSC 83265, Tritylcysteine",KIF11,Mitosis,,,,NSC 83265; S-Trityl-L-cysteine; Tritylcysteine,KIF11
salermide,,,,,,,salermide,SIRT1; SIRT2,inhibitor of sirtuin 1 and sirtuin 2,salermide,SIRT2; SIRT1
salermide:plx-4032 (12:1 mol/mol),,,,,,,salermide:PLX-4032 (12:1 mol/mol),SIRT1; SIRT2; BRAF,inhibitor of sirtuin 1 and sirtuin 2;inhibitor of BRAF,salermide:PLX-4032 (12:1 mol/mol),BRAF; SIRT2; SIRT1
salubrinal,,,Salubrinal,EIF-2alpha Inhibitor,EIF2A,Other,,,,EIF-2alpha Inhibitor; Salubrinal,EIF2A
saracatinib,AZD0530,ABL,Saracatinib,"AZD0530, AZD-0530, AZ-10353926",ABL; SRC,RTK signaling,saracatinib,ABL1; SRC,inhibitor of SRC and ABL1,AZD0530; AZD-0530; AZ-10353926; saracatinib; Saracatinib,ABL; ABL1; SRC
sb-225002,,,,,,,SB-225002,CXCR2,inhibitor of chemokine receptor 2,SB-225002,CXCR2
sb-431542,,,,,,,SB-431542,TGFBR1,inhibitor of the transforming growth factor beta type 1 receptor,SB-431542,TGFBR1
sb-525334,,,,,,,SB-525334,TGFBR1,inhibitor of the transforming growth factor beta type 1 receptor,SB-525334,TGFBR1
sb-743921,,,,,,,SB-743921,KIF11,inhibitor of kinesin 11,SB-743921,KIF11
sb216763,,,SB216763,"SB-216763, SB 216763",GSK3A; GSK3B,WNT signaling,,,,SB-216763; SB 216763; SB216763,GSK3B; GSK3A
sb505124,,,SB505124,"SB 505124, SB505124",ALK4; ALK5,RTK signaling,,,,SB 505124; SB505124,ALK4; ALK5
sb52334,,,SB52334,"SB-52334, SB 52334",ALK5,RTK signaling,,,,SB 52334; SB-52334; SB52334,ALK5
sb590885,,,SB590885,SB-590885,BRAF,ERK MAPK signaling,,,,SB590885; SB-590885,BRAF
sch-529074,,,,,,,SCH-529074,TP53,activator of mutant p53,SCH-529074,TP53
sch-79797,,,,,,,SCH-79797,F2R,antagonist of proteinase-activated receptor 1 (PAR1),SCH-79797,F2R
seliciclib,,,Seliciclib,"Roscovitine, CYC-202, AL-39256",CDK2; CDK7; CDK9,Cell cycle,,,,CYC-202; Seliciclib; Roscovitine; AL-39256,CDK7; CDK2; CDK9
selisistat,,,Selisistat,"EX-527, EX 527",SIRT1,Chromatin histone acetylation,EX-527,SIRT1,inhibitor of sirtuin 1,EX-527; Selisistat; EX 527,SIRT1
selumetinib,AZD6244,MEK,Selumetinib,"AZD6244, AZD-6244, ARRY-886",MEK1; MEK2,ERK MAPK signaling,selumetinib,MAP2K1; MAP2K2,inhibitor of MEK1 and MEK2,Selumetinib; ARRY-886; selumetinib; AZD-6244; AZD6244,MEK1; MEK2; MAP2K2; MAP2K1; MEK
selumetinib:brd-a02303741 (4:1 mol/mol),,,,,,,selumetinib:BRD-A02303741 (4:1 mol/mol),MAP2K1; MAP2K2; DOT1L,inhibitor of MEK1 and MEK2;inhibitor of histone methyltransferases,selumetinib:BRD-A02303741 (4:1 mol/mol),MAP2K1; DOT1L; MAP2K2
selumetinib:decitabine (4:1 mol/mol),,,,,,,selumetinib:decitabine (4:1 mol/mol),MAP2K1; MAP2K2; DNMT1,inhibitor of MEK1 and MEK2;inhibitor of DNA methyltransferase,selumetinib:decitabine (4:1 mol/mol),MAP2K1; DNMT1; MAP2K2
selumetinib:gdc-0941 (4:1 mol/mol),,,,,,,selumetinib:GDC-0941 (4:1 mol/mol),MAP2K1; MAP2K2; PIK3CA; PIK3CB; PIK3CD; PIK3CG,inhibitor of MEK1 and MEK2;inhibitor of PI3K kinase activity,selumetinib:GDC-0941 (4:1 mol/mol),PIK3CA; MAP2K2; MAP2K1; PIK3CB; PIK3CG; PIK3CD
selumetinib:jq-1 (4:1 mol/mol),,,,,,,selumetinib:JQ-1 (4:1 mol/mol),MAP2K1; MAP2K2; BRDT,inhibitor of MEK1 and MEK2;inhibitor of bromodomain (BRD) and extra-C terminal domain (BET) proteins,selumetinib:JQ-1 (4:1 mol/mol),MAP2K1; BRDT; MAP2K2
selumetinib:mk-2206 (8:1 mol/mol),,,,,,,selumetinib:MK-2206 (8:1 mol/mol),MAP2K1; MAP2K2; AKT1,inhibitor of MEK1 and MEK2;inhibitor of AKT1,selumetinib:MK-2206 (8:1 mol/mol),MAP2K1; AKT1; MAP2K2
selumetinib:navitoclax (8:1 mol/mol),,,,,,,selumetinib:navitoclax (8:1 mol/mol),MAP2K1; MAP2K2; BCL2; BCL2L1; BCL2L2,"inhibitor of MEK1 and MEK2;inhibitor of BCL2, BCL-xL, and BCL-W",selumetinib:navitoclax (8:1 mol/mol),BCL2; BCL2L2; BCL2L1; MAP2K2; MAP2K1
selumetinib:piperlongumine (8:1 mol/mol),,,,,,,selumetinib:piperlongumine (8:1 mol/mol),MAP2K1; MAP2K2,inhibitor of MEK1 and MEK2;natural product; modulator of ROS levels,selumetinib:piperlongumine (8:1 mol/mol),MAP2K1; MAP2K2
selumetinib:plx-4032 (8:1 mol/mol),,,,,,,selumetinib:PLX-4032 (8:1 mol/mol),MAP2K1; MAP2K2; BRAF,inhibitor of MEK1 and MEK2;inhibitor of BRAF,selumetinib:PLX-4032 (8:1 mol/mol),MAP2K1; BRAF; MAP2K2
selumetinib:tretinoin (2:1 mol/mol),,,,,,,selumetinib:tretinoin (2:1 mol/mol),MAP2K1; MAP2K2; RARA; RARB; RARG,inhibitor of MEK1 and MEK2;agonist of retinoid acid receptors,selumetinib:tretinoin (2:1 mol/mol),RARG; RARA; RARB; MAP2K1; MAP2K2
selumetinib:unc0638 (4:1 mol/mol),,,,,,,selumetinib:UNC0638 (4:1 mol/mol),MAP2K1; MAP2K2; EHMT1; EHMT2,inhibitor of MEK1 and MEK2;inhibitor of EHMT2 and GLP methyltransferase,selumetinib:UNC0638 (4:1 mol/mol),MAP2K1; EHMT1; EHMT2; MAP2K2
selumetinib:vorinostat (8:1 mol/mol),,,,,,,selumetinib:vorinostat (8:1 mol/mol),MAP2K1; MAP2K2; HDAC1; HDAC2; HDAC3; HDAC6; HDAC8,"inhibitor of MEK1 and MEK2;inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8",selumetinib:vorinostat (8:1 mol/mol),HDAC8; HDAC1; HDAC3; HDAC2; MAP2K2; MAP2K1; HDAC6
semagacestat,,,,,,,semagacestat,APH1A; NCSTN; PSEN1; PSENEN,inhibitor of gamma-secretase,semagacestat,PSEN1; APH1A; NCSTN; PSENEN
sepantronium bromide,,,Sepantronium bromide,"YM155, YM-155, YM 155",BIRC5,Apoptosis regulation,YM-155,BIRC5,inhibitor of survivin expression,Sepantronium bromide; YM 155; YM155; YM-155,BIRC5
serdemetan,,,Serdemetan,JNJ-26854165,MDM2,p53 pathway,serdemetan,MDM2,inhibitor of MDM2,JNJ-26854165; Serdemetan; serdemetan,MDM2
serdemetan:sch-529074 (1:1 mol/mol),,,,,,,serdemetan:SCH-529074 (1:1 mol/mol),MDM2; TP53,inhibitor of MDM2;activator of mutant p53,serdemetan:SCH-529074 (1:1 mol/mol),TP53; MDM2
sgc0946,,,SGC0946,,DOT1L,Chromatin histone methylation,,,,SGC0946,DOT1L
sgx-523,,,,,,,SGX-523,MET,inhibitor of MET,SGX-523,MET
shikonin,,,Shikonin,Anchusin,not defined,Other,,,,Anchusin; Shikonin,not defined
sid 26681509,,,,,,,SID 26681509,CTSL1,inhibitor of cathepsin L,SID 26681509,CTSL1
sildenafil,,,,,,,sildenafil,PDE5A,inhibitor of phosphodiesterase 5A,sildenafil,PDE5A
silmitasertib,,,,,,,silmitasertib,CSNK2A1; CSNK2A2,inhibitor of casein kinase 2,silmitasertib,CSNK2A1; CSNK2A2
simvastatin,,,,,,,simvastatin,HMGCR,inhibitor of HMG-CoA reductase,simvastatin,HMGCR
sirolimus,,,Rapamycin,"AY-22989, Sirolimus, WY-090217, Torisel, Rapamune",MTORC1,PI3K/MTOR signaling,sirolimus,MTOR,inhibitor of mTOR,WY-090217; AY-22989; Sirolimus; Torisel; Rapamycin; Rapamune; sirolimus,MTORC1; MTOR
sirolimus:bortezomib (250:1 mol/mol),,,,,,,sirolimus:bortezomib (250:1 mol/mol),MTOR; PSMB1; PSMB2; PSMB5; PSMD1; PSMD2,inhibitor of mTOR;inhibitor of 26S proteasome,sirolimus:bortezomib (250:1 mol/mol),PSMB5; PSMD2; PSMB2; PSMD1; MTOR; PSMB1
sitagliptin,,,,,,,sitagliptin,DPP4,inhibitor of dipetidyl peptidase-4,sitagliptin,DPP4
sj-172550,,,,,,,SJ-172550,MDM2; TP53,inhibitor of p53-MDM2 interaction,SJ-172550,TP53; MDM2
skepinone-l,,,,,,,skepinone-L,MAPK14,inhibitor of p38 MAPK,skepinone-L,MAPK14
ski-ii,,,,,,,SKI-II,SPHK1,inhibitor of sphingosine kinase 1,SKI-II,SPHK1
sl0101,,,SL0101,"SL-0101, SL 0101-1",RSK; AURKB; PIM1; PIM3,Other,,,,SL0101; SL 0101-1; SL-0101,PIM1; PIM3; RSK; AURKB
smer-3,,,,,,,SMER-3,CUL1; SKP1,inhibitor of E3-ubiquitin ligase,SMER-3,SKP1; CUL1
sn-38,,,SN-38,"7-Ethyl-10-Hydroxy-Camptothecin, SN 38",TOP1,DNA replication,SN-38,TOP1,metabolite of irinotecan; inhibitor of topoisomerase I,7-Ethyl-10-Hydroxy-Camptothecin; SN 38; SN-38,TOP1
sns-032,,,,,,,SNS-032,CDK16; CDK17; CDK2; CDK7; CDK9; CDKL5,inhibitor of cyclin-dependent kinases,SNS-032,CDK17; CDK2; CDK16; CDKL5; CDK9; CDK7
snx-2112,,,SNX-2112,SNX 2112,HSP90,Protein stability and degradation,SNX-2112,HSP90AA1; HSP90B1,inhibitor of HSP90alpha and HSP90beta,SNX 2112; SNX-2112,HSP90AA1; HSP90; HSP90B1
snx-2112:bortezomib (250:1 mol/mol),,,,,,,SNX-2112:bortezomib (250:1 mol/mol),HSP90AA1; HSP90B1; PSMB1; PSMB2; PSMB5; PSMD1; PSMD2,inhibitor of HSP90alpha and HSP90beta;inhibitor of 26S proteasome,SNX-2112:bortezomib (250:1 mol/mol),PSMB5; HSP90AA1; PSMD2; PSMB2; PSMD1; HSP90B1; PSMB1
sorafenib,Sorafenib,RTK,Sorafenib,"Nexavar, 284461-73-0, BAY 43-9006",PDGFR; KIT; VEGFR; RAF,RTK signaling,sorafenib,BRAF; FLT3; KDR; RAF1,"inhibitor of BRAF, CRAF, and VEGFR2",sorafenib; Nexavar; Sorafenib; 284461-73-0; BAY 43-9006,KDR; BRAF; PDGFR; RTK; VEGFR; RAF1; KIT; RAF; FLT3
sotrastaurin,,,,,,,sotrastaurin,PRKCB,inhibitor of protein kinase C beta,sotrastaurin,PRKCB
spautin-1,,,,,,,spautin-1,USP10; USP13,inhibitor of the deubiquitinase activity of USP13 and USP10,spautin-1,USP13; USP10
sr-ii-138a,,,,,,,SR-II-138A,EIF4A2; EIF4E; EIF4G1,silvestrol analog; inhibits translation by modulating the eIF4F complex,SR-II-138A,EIF4E; EIF4G1; EIF4A2
sr1001,,,,,,,SR1001,RORA; RORC,synthetic ROR ligand; suppressor of TH17 differentiation,SR1001,RORC; RORA
sr8278,,,,,,,SR8278,NR1D1,antagonist of Rev-ErbAalpha,SR8278,NR1D1
srt-1720,,,,,,,SRT-1720,SIRT1,activator of sirtuin-1,SRT-1720,SIRT1
staurosporine,,,,,,,staurosporine,,inhibitor of multiple kinases,staurosporine,NaN
stemregenin 1,,,,,,,StemRegenin 1,AHR,inhibitor of aryl hydrocarbon receptor,StemRegenin 1,AHR
stf-31,,,,,,,STF-31,NAMPT,inhibitor of nicotinamide phosphoribosyltransferase,STF-31,NAMPT
stf-62247,,,STF-62247,STF62247,Autophagy inducer,Other,,,,STF-62247; STF62247,Autophagy inducer
su11274,,,,,,,SU11274,MET,inhibitor of MET,SU11274,MET
sunitinib,,,Sunitinib,"Sutent, Sunitinib Malate, SU-11248",PDGFR; KIT; VEGFR; FLT3; RET; CSF1R,RTK signaling,sunitinib,FLT1; FLT3; KDR; KIT; PDGFRA; PDGFRB,"inhibitor of VEGFRs, c-KIT, and PDGFR alpha and beta",Sunitinib; Sunitinib Malate; Sutent; sunitinib; SU-11248,KDR; PDGFRB; PDGFRA; PDGFR; VEGFR; RET; KIT; CSF1R; FLT1; FLT3
sz4ta2,,,,,,,SZ4TA2,BCL2L1,inhibitor of BCL-xL,SZ4TA2,BCL2L1
t0901317,,,T0901317,"TO-901317, TO901317",LXR; FXR,Other,,,,T0901317; TO-901317; TO901317,FXR; LXR
tacedinaline,,,,,,,tacedinaline,HDAC1; HDAC2; HDAC3; HDAC6; HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8",tacedinaline,HDAC8; HDAC1; HDAC3; HDAC2; HDAC6
tacrolimus,,,,,,,tacrolimus,PPP3CA; PPP3CB; PPP3CC; PPP3R1; PPP3R2,inhibitor of calcineurin,tacrolimus,PPP3CC; PPP3CA; PPP3CB; PPP3R2; PPP3R1
tae684,TAE684,ALK,NVP-TAE684,"NVP-TAE 684, TAE684, TAE-684",ALK,RTK signaling,NVP-TAE684,ALK,inhibitor of ALK and ALK-NPM fusion protein,TAE684; NVP-TAE684; NVP-TAE 684; TAE-684,ALK
tak-715,,,TAK-715,"KIN001-201, TAK 715",p38alpha; p38beta,JNK and p38 signaling,,,,KIN001-201; TAK 715; TAK-715,p38alpha; p38beta
talazoparib,,,Talazoparib,"BMN-673, BMN 973",PARP1; PARP2,Genome integrity,,,,BMN-673; BMN 973; Talazoparib,PARP1; PARP2
tamatinib,,,,,,,tamatinib,SYK,inhibitor of spleen tyrosine kinase,tamatinib,SYK
tamoxifen,,,Tamoxifen,"Nolvadex, Soltamox, Zynoplex, ICI-46474, Kessar",ESR1,Hormone-related,tamoxifen,ESR1; ESR2,modulator of estrogen receptors,Soltamox; ICI-46474; tamoxifen; Tamoxifen; Kessar; Nolvadex; Zynoplex,ESR1; ESR2
tandutinib,,,,,,,tandutinib,FLT3; KIT,inhibitor of c-KIT and VEGFR3,tandutinib,KIT; FLT3
tanespimycin,17-AAG,HSP90,Tanespimycin,"17-AAG, BMS-722782",HSP90,Protein stability and degradation,tanespimycin,HSP90AA1,inhibitor of HSP90,tanespimycin; Tanespimycin; BMS-722782; 17-AAG,HSP90AA1; HSP90
tanespimycin:bortezomib (250:1 mol/mol),,,,,,,tanespimycin:bortezomib (250:1 mol/mol),HSP90AA1; PSMB1; PSMB2; PSMB5; PSMD1; PSMD2,inhibitor of HSP90;inhibitor of 26S proteasome,tanespimycin:bortezomib (250:1 mol/mol),PSMB5; HSP90AA1; PSMD2; PSMB2; PSMD1; PSMB1
tanespimycin:gemcitabine (1:1 mol/mol),,,,,,,tanespimycin:gemcitabine (1:1 mol/mol),HSP90AA1; CMPK1; RRM1; TYMS,"inhibitor of HSP90;inhibitor of DNA replication; inhibitor of ribonucleotide reductase, thymidylate synthetase, and cytidine monophosphate (UMP-CMP) kinase ",tanespimycin:gemcitabine (1:1 mol/mol),CMPK1; HSP90AA1; TYMS; RRM1
temozolomide,,,Temozolomide,"Temodar, Temodal, M-39831, SCH 52365",DNA alkylating agent,DNA replication,temozolomide,,DNA alkylator,temozolomide; M-39831; Temodar; Temodal; SCH 52365; Temozolomide,DNA alkylating agent
temsirolimus,,,Temsirolimus,"CCI-779, Torisel",MTOR,PI3K/MTOR signaling,temsirolimus,MTOR,inhibitor of mTOR,Temsirolimus; temsirolimus; CCI-779; Torisel,MTOR
teniposide,,,,,,,teniposide,TOP2A; TOP2B,inhibitor of topoisomerase II,teniposide,TOP2B; TOP2A
tg-100-115,,,,,,,TG-100-115,PIK3CD; PIK3CG,inhibitor of PI3K catalytic subunits delta and gamma,TG-100-115,PIK3CG; PIK3CD
tgx221,,,TGX221,"TGX-221, Tgx 221",PI3Kbeta,PI3K/MTOR signaling,TGX-221,PIK3CB,inhibitor of PI3K catalytic subunit beta,TGX-221; Tgx 221; TGX221,PIK3CB; PI3Kbeta
thalidomide,,,,,,,thalidomide,CRBN,immunomodulatory drug; binder of cereblon,thalidomide,CRBN
thapsigargin,,,Thapsigargin,Octanoic acid,SERCA,Other,,,,Octanoic acid; Thapsigargin,SERCA
thz-2-102-1,,,THZ-2-102-1,,CDK7,Cell cycle,,,,THZ-2-102-1,CDK7
thz-2-49,,,THZ-2-49,,CDK9,Cell cycle,,,,THZ-2-49,CDK9
tigecycline,,,,,,,tigecycline,,analog of tetracycline,tigecycline,NaN
tipifarnib,,,Tipifarnib,Zarnestra,Farnesyl-transferase (FNTA),Other,,,,Tipifarnib; Zarnestra,Farnesyl-transferase (FNTA)
tipifarnib-p1,,,,,,,tipifarnib-P1,FNTA,inhibitor of farnesyltransferase,tipifarnib-P1,FNTA
tipifarnib-p2,,,,,,,tipifarnib-P2,FNTA,inhibitor of farnesyltransferase,tipifarnib-P2,FNTA
tivantinib,,,,,,,tivantinib,MET,inhibitor of MET; inhibitor of microtubule assembly,tivantinib,MET
tivozanib,,,Tivozanib,"AV-951, AV 951, KRN-951, KIL8951, ASP-4130",VEGFR1; VEGFR2; VEGFR3,RTK signaling,tivozanib,FLT1; FLT3; KDR,inhibitor of VEGFRs,AV-951; KIL8951; AV 951; KRN-951; ASP-4130; Tivozanib; tivozanib,VEGFR3; KDR; VEGFR2; VEGFR1; FLT1; FLT3
tki258,TKI258,FGFR,,,,,,,,TKI258,FGFR
tl-1-85,,,TL-1-85,,TAK,"Other, kinases",,,,TL-1-85,TAK
tl-2-105,,,TL-2-105,,not defined,Unclassified,,,,TL-2-105,not defined
topotecan,Topotecan,TOP1,,,,,topotecan,TOP1,inhibitor of topoisomerase I,topotecan; Topotecan,TOP1
tosedostat,,,,,,,tosedostat,ANPEP; LAP3; NPEPPS,"inhibitor of leucine aminopeptidase 3 (LAP), puromycin-sensitive aminopeptidase (PuSA), and aminopeptidase N",tosedostat,LAP3; ANPEP; NPEPPS
tozasertib,,,Tozasertib,"MK 0457,MK-0457,MK-045, VX-680 VX 680 VX-68",AURKA; AURKB; AURKC; others,Mitosis,,,,"MK 0457,MK-0457,MK-045; VX-680 VX 680 VX-68; Tozasertib",others; AURKA; AURKC; AURKB
tpca-1,,,TPCA-1,,IKK2,"Other, kinases",TPCA-1,IKBKB,inhibitor of IKK-2,TPCA-1,IKK2; IKBKB
trametinib,,,Trametinib,"GSK1120212, Mekinist",MEK1; MEK2,ERK MAPK signaling,trametinib,MAP2K1; MAP2K2,inhibitor of MEK1 and MEK2,Mekinist; Trametinib; trametinib; GSK1120212,MAP2K1; MEK1; MEK2; MAP2K2
tretinoin,,,Tretinoin,"ATRA, Vesanoid, Renova, Atralin, Tretin-X, Avita",Retinoic acid ,Other,tretinoin,RARA; RARB; RARG,agonist of retinoid acid receptors,Avita; ATRA; Tretinoin; Tretin-X; Atralin; tretinoin; Renova; Vesanoid,RARG; Retinoic acid ; RARA; RARB
tretinoin:carboplatin (2:1 mol/mol),,,,,,,tretinoin:carboplatin (2:1 mol/mol),RARA; RARB; RARG,agonist of retinoid acid receptors;inducer of DNA damage,tretinoin:carboplatin (2:1 mol/mol),RARG; RARA; RARB
tretinoin:navitoclax (4:1 mol/mol),,,,,,,tretinoin:navitoclax (4:1 mol/mol),RARA; RARB; RARG; BCL2; BCL2L1; BCL2L2,"agonist of retinoid acid receptors;inhibitor of BCL2, BCL-xL, and BCL-W",tretinoin:navitoclax (4:1 mol/mol),BCL2; RARG; BCL2L2; BCL2L1; RARA; RARB
triazolothiadiazine,,,,,,,triazolothiadiazine,PDE4A; PDE4B; PDE4D,inhibitor of phosphdiesterase 4A/B/D,triazolothiadiazine,PDE4D; PDE4A; PDE4B
trifluoperazine,,,,,,,trifluoperazine,DRD2,antagonist of dopamine receptor D2,trifluoperazine,DRD2
triptolide,,,,,,,triptolide,,natural product; inhibitor of RNA polymerase II,triptolide,NaN
tubastatin a,,,Tubastatin A,,HDAC1; HDAC6; HDAC8,Chromatin histone acetylation,tubastatin A,HDAC6,inhibitor of tubulin deacetylase activity of HDAC6,tubastatin A; Tubastatin A,HDAC1; HDAC8; HDAC6
tw-37,,,TW 37,"TW37, TW-37",BCL2; BCL-XL; MCL1,Apoptosis regulation,TW-37,BCL2; BCL2L1,inhibitor of BCL2 and BCL-xL,TW37; TW-37; TW 37,BCL2; MCL1; BCL2L1; BCL-XL
unc0321,,,,,,,UNC0321,EHMT2,inhibitor of G9a histone methyltransferase,UNC0321,EHMT2
unc0638,,,UNC0638,"UNC-0638, UNC 0683",G9a and GLP methyltransferases,Chromatin histone methylation,UNC0638,EHMT1; EHMT2,inhibitor of EHMT2 and GLP methyltransferase,UNC-0638; UNC0638; UNC 0683,EHMT1; EHMT2; G9a and GLP methyltransferases
unc0638:navitoclax (1:1 mol/mol),,,,,,,UNC0638:navitoclax (1:1 mol/mol),EHMT1; EHMT2; BCL2; BCL2L1; BCL2L2,"inhibitor of EHMT2 and GLP methyltransferase;inhibitor of BCL2, BCL-xL, and BCL-W",UNC0638:navitoclax (1:1 mol/mol),BCL2; BCL2L2; EHMT1; BCL2L1; EHMT2
unc1215,,,UNC1215,UNC-1215,L3MBTL3,Chromatin other,,,,UNC-1215; UNC1215,L3MBTL3
vaf-347,,,,,,,VAF-347,AHR,inhibitor of aryl hydrocarbon receptor,VAF-347,AHR
valdecoxib,,,,,,,valdecoxib,PTGS2,inhibitor of cyclooxygenase-2 (COX2),valdecoxib,PTGS2
vandetanib,,,,,,,vandetanib,EGFR; KDR,inhibitor of VEGFR2 and EGFR,vandetanib,EGFR; KDR
veliparib,,,Veliparib,"ABT-888, ABT888, ABT 888",PARP1; PARP2,Genome integrity,veliparib,PARP1; PARP2,inhibitor of poly (ADP-ribose) polymerase 1 (PARP1) and 2 (PARP2),ABT 888; Veliparib; veliparib; ABT888; ABT-888,PARP1; PARP2
ver-155008,,,,,,,VER-155008,HSPA1A; HSPA1B; HSPA1L,inhibitor of HSP70,VER-155008,HSPA1A; HSPA1B; HSPA1L
vinblastine,,,Vinblastine,Velban,Microtubule destabiliser,Mitosis,,,,Vinblastine; Velban,Microtubule destabiliser
vincristine,,,,,,,vincristine,,inhibitor of mictrotubule assembly,vincristine,NaN
vinorelbine ,,,Vinorelbine ,"vinorelbine tartrate, Navelbine, Exelbine",Microtubule destabiliser,Mitosis,,,,Navelbine; Exelbine; Vinorelbine ; vinorelbine tartrate,Microtubule destabiliser
vismodegib,,,Vismodegib,"GDC0449, Erivedge",SMO,Other,,,,Vismodegib; Erivedge; GDC0449,SMO
vnlg/124,,,VNLG/124,HDAC inhibitor XV,"HDAC,RAR",Chromatin histone acetylation,,,,HDAC inhibitor XV; VNLG/124,"HDAC,RAR"
vorapaxar,,,,,,,vorapaxar,F2R,antagonist of proteinase-activated receptor 1 (PAR1),vorapaxar,F2R
vorinostat,,,Vorinostat,"Zolinza, SAHA, suberanilohydroxamic acid, suberoylanilide hydroxamic acid, MK-0683",HDAC inhibitor Class I; IIa; IIb; IV,Chromatin histone acetylation,vorinostat,HDAC1; HDAC2; HDAC3; HDAC6; HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8",suberoylanilide hydroxamic acid; vorinostat; suberanilohydroxamic acid; SAHA; MK-0683; Zolinza; Vorinostat,IIa; HDAC8; HDAC1; HDAC3; IV; HDAC2; HDAC inhibitor Class I; IIb; HDAC6
vorinostat:carboplatin (1:1 mol/mol),,,,,,,vorinostat:carboplatin (1:1 mol/mol),HDAC1; HDAC2; HDAC3; HDAC6; HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8;inducer of DNA damage",vorinostat:carboplatin (1:1 mol/mol),HDAC8; HDAC1; HDAC3; HDAC2; HDAC6
vorinostat:navitoclax (4:1 mol/mol),,,,,,,vorinostat:navitoclax (4:1 mol/mol),HDAC1; HDAC2; HDAC3; HDAC6; HDAC8; BCL2; BCL2L1; BCL2L2,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8;inhibitor of BCL2, BCL-xL, and BCL-W",vorinostat:navitoclax (4:1 mol/mol),HDAC8; HDAC1; BCL2; BCL2L2; HDAC3; BCL2L1; HDAC2; HDAC6
vu0155056,,,,,,,VU0155056,PLD1; PLD2,inhibitor of phospholipase D1/D2,VU0155056,PLD2; PLD1
vx-11e,,,VX-11e,"VX11e, VX11e",ERK2,ERK MAPK signaling,,,,VX-11e; VX11e,ERK2
vx-680,,,,,,,VX-680,AURKA; AURKB; AURKC,inhibitor of aurora kinases,VX-680,AURKA; AURKC; AURKB
vx-702,,,VX-702,"VX702, VX 702",p38,JNK and p38 signaling,,,,VX702; VX-702; VX 702,p38
way-362450,,,,,,,WAY-362450,NR1H4,agonist of farnesoid X receptor,WAY-362450,NR1H4
wee1 inhibitor,,,Wee1 Inhibitor,"681640, Wee1 Inhibitor",WEE1; CHEK1,Cell cycle,,,,681640; Wee1 Inhibitor,CHEK1; WEE1
wh-4-023,,,WH-4-023,KIN001-112,SRC; LCK,"Other, kinases",,,,KIN001-112; WH-4-023,LCK; SRC
whi-p97,,,WHI-P97,"AC1L1GQE, KIN001-055",JAK3,"Other, kinases",,,,WHI-P97; KIN001-055; AC1L1GQE,JAK3
wp1130,,,,,,,WP1130,UCHL5; USP14; USP5; USP9X,"inhibitor of the deubiquitinase activity of USP9X, USP5, USP14, and UCH37",WP1130,USP5; UCHL5; USP14; USP9X
wz-1-84,,,WZ-1-84,KIN001-123,BMX,"Other, kinases",,,,WZ-1-84; KIN001-123,BMX
wz3105,,,WZ3105,,SRC; ROCK2; NTRK2; FLT3; IRAK1; others,Other,,,,WZ3105,ROCK2; NTRK2; SRC; others; IRAK1; FLT3
wz4002,,,,,,,WZ4002,EGFR,inhibitor of EGFR targeting T790M resistance,WZ4002,EGFR
wz8040,,,,,,,WZ8040,EGFR,inhibitor of EGFR targeting T790M resistance,WZ8040,EGFR
xav939,,,XAV939,"NVP-XAV939, XAV-939, XAV 939",TNKS1; TNKS2,WNT signaling,,,,XAV939; XAV 939; XAV-939; NVP-XAV939,TNKS2; TNKS1
xl765,,,,,,,XL765,MTOR; PIK3CA; PIK3CB; PIK3CD; PIK3CG; PRKDC,inhibitor of mTOR and PI3K kinase acitivities,XL765,PRKDC; PIK3CA; MTOR; PIK3CB; PIK3CG; PIK3CD
xmd11-85h,,,XMD11-85h,,BRSK2; FLT4; MARK4; PRKCD; RET; SPRK1,Other,,,,XMD11-85h,PRKCD; FLT4; SPRK1; RET; BRSK2; MARK4
xmd13-2,,,XMD13-2,,RIPK1,Apoptosis regulation,,,,XMD13-2,RIPK1
xmd14-99,,,XMD14-99,,ALK; CDK7; LTK; others,Other,,,,XMD14-99,ALK; LTK; others; CDK7
xmd15-27,,,XMD15-27,,CAMK2,"Other, kinases",,,,XMD15-27,CAMK2
xmd8-85,,,XMD8-85,ERK5-IN-1,ERK5; BET,Other,,,,XMD8-85; ERK5-IN-1,ERK5; BET
xmd8-92,,,XMD8-92,XMD 8-92,MAPK7,"Other, kinases",,,,XMD8-92; XMD 8-92,MAPK7
y-39983,,,Y-39983,,ROCK,Cytoskeleton,,,,Y-39983,ROCK
yk-4-279,,,YK-4-279,YK 4-279,RNA helicase A,Other,YK 4-279,DHX9; ERG; ETV1,inhibitor of RNA helicase A (RHA) binding to EWS-FLI1; inhibitor of ERG and ETV1 activity,YK-4-279; YK 4-279,RNA helicase A; DHX9; ERG; ETV1
yl54,,,,,,,YL54,,stapled helical peptide,YL54,NaN
ym201636,,,YM201636,"YM-201636, YM 201636",PYKFYVE,Other,,,,YM201636; YM 201636; YM-201636,PYKFYVE
z-llnle-cho,,,Z-LLNle-CHO,"Z-L-Norleucine-CHO, Gamma-Secretase Inhibitor 1",gamma-secretase,Other,,,,Gamma-Secretase Inhibitor 1; Z-L-Norleucine-CHO; Z-LLNle-CHO,gamma-secretase
zd-6474,ZD-6474,EGFR,,,,,,,,ZD-6474,EGFR
zebularine,,,,,,,zebularine,DNMT1,inhibitor of DNA methyltransferases,zebularine,DNMT1
zg-10,,,ZG-10,,JNK1,JNK and p38 signaling,,,,ZG-10,JNK1
zibotentan,,,Zibotentan,"ZD4054, ZD-4054",Endothelin-1 receptor (EDNRA),Other,,,,Zibotentan; ZD4054; ZD-4054,Endothelin-1 receptor (EDNRA)
zm447439,,,ZM447439,"ZM-447439, ZM 447439",AURKA; AURKB,Mitosis,,,,ZM447439; ZM 447439; ZM-447439,AURKA; AURKB
zstk474,,,ZSTK474,"KIN001-167, ZSTK-474, ZSTK 474",PI3K (class 1),PI3K/MTOR signaling,ZSTK474,PIK3CB; PIK3CD; PIK3CG,"inhibitor of PI3K catalytic subunits beta, delta, and gamma",ZSTK-474; ZSTK 474; ZSTK474; KIN001-167,PI3K (class 1); PIK3CB; PIK3CG; PIK3CD
